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Abstract
Gene mutations in the leucine-rich repeat kinase 2 (LRRK2) are the most common cause
of autosomal dominant Parkinson’s Disease (PD) and elevated levels of hLRRK2 mutant
variants in Drosophila induces PD. Here, we introduced the human LRRK2 (R1441C)
variant in dopaminergic neurons of flies and observed a reduced locomotor activity, an
age dependent degeneration of dopaminergic neurons, and shorter lifetime. To better
understand the hLRRK2 (R1441C) induced pathobiology, we performed stable isotope
labeling in fly to accurately quantify the proteome and phosphoproteome dynamics.
We quantified almost 3000 proteins and found several regulated cytoskeletal, mitochon-
drial, and synaptic vesicle (SV) proteins in our PD fly model. To explore the hLRRK2
(R1441C) function more precisely, we compared our model to three different α-Synuclein
(αS) overexpressing fly strains (αS, αS-A30P, αS-A53T), which show a similar PD phe-
notype but distinct pathobiology mechanisms. For example, synaptotagmin, syntaxin
and rab3 were only affected in hLRRK2 (R1441C) flies compared to all other tested
fly strains. Moreover, our global phosphoproteome analysis revealed several synaptic
vesicle proteins with enhanced phosphorylation, including synaptojanin (pT1131)and
we show that the conserved phosphorylation site on human synaptojanin is modulated
by the hLRRK2 (R1441C) mutant variant. Consistently, a protein-protein interaction
screen confirmed that hLRRK2 is tightly associated with synaptic vesicle proteins. Thus,
our results provide a systemic view on the pathobiology mechanism caused by hLRRK
and αS overexpression and suggest that the increased kinase activity of the hLRRK2
(R1441C) mutant results in enhanced phosphorylation of synaptojanin. These find-
ings may contribute to develop new therapeutic strategies to prevent hLRRK2-induced
Parkinson disease.
Acknowledgements
There are so many people who have contributed in different ways to get me close to
where I stand today- the completion of PhD thesis. I would like to begin by thanking
my parents, MD Gias Uddin Ahmed and Rezia Begum for their biased love and support
throughout my life. Without your continuous prayer, enthusiastic encouragement and
inspiration, I would have never materialized the successful completion of the thesis.
I would like to offer my special thanks and gratitude to my PhD thesis supervisor PD.
Dr. Hermann Heumann for his encouragement, detailed guidance, direction and active
participation in discussions and comments throughout my thesis work.
I am really grateful to Prof. Marcus Krueger, for his sincere guidance, direction and
advice throughout my PhD. I was always inspired by his love of rigorous science, great
vision, and marvelous creativity. He tried his best in every aspect to assist my research
and i am truly thankful for having his support and encouragement throughout my career.
I would extend my deep gratitude towards my Co-supervisor Prof. Rolf Heumann for
his valuable feedback and suggestions which helped me to resolve burning questions and
concerns. I am very grateful to my collaborator, Prof. Bernhard Hovemann and Dr.
Anna Ziegler for their tremendous assistance in generating various genotypes flies for
my research and has been offering insightful comments on the biological aspects of my
findings.
I would also like to thank my peers, especially Hendrik Nolte, Sriram Aravamudhan for
their offering of help, advice, and insightful scientific discussions. Suraya Hoelper and
Sylvia Jeratsch deserve notable mentions for making my time enjoyable in the group!
Prof. Dr. Chris Turck, Prof. Dr. Thomas Carell and Prof. Dr. Foerstemann deserve
hearty thanks for being part of my thesis committee.
Apart from the above, there are several individuals whose direct involvement deserves
mighty thanks. I would like to share appreciation for Dr. Atikur Rahman Jewel and
Zahed Zia for all the encouragements and motivations provided when I felt down spirited.
Immense gratitude to Katja Schoder and Sebastian Schmidt for their administrative
helps during my thesis. I also want to give thanks to my friend Abdullah Al Mamun,
Sharif Mortoga Chowdhury, Arif Mortoga Chowdhury, Soyeb, S M Majedul Karim, Shafi
Jamali, Murad Hossain, Sumit Anik, Munich Masti Group and Tabur Tal Matal Group
for bringing lots of joy and fun. I have enjoyed very much spending time in such an
interesting, fun, and Masti group!
iv
Finally, I would like to thank the almighty Allah the most merciful and most beneficent
for keeping me fit and committed in finishing the academic targets that I set for.
Md. Shariful Islam
Contents
Abstract iii
Acknowledgements iv
Contents vi
List of Figures ix
List of Tables xi
Abbreviations xii
1 Introduction 1
1.1 Parkinson’s disease (PD) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 PD Features . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.3 Risk factors and Genes Association of PD . . . . . . . . . . . . . . . . . . 3
1.3.1 Alpha-synuclein . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.3.2 Parkin, PINK1, DJ-1, UCH-L1 . . . . . . . . . . . . . . . . . . . . 3
1.3.3 Leucine-rich repeat kinase 2 ( LRRK2; PARK8) . . . . . . . . . . 4
1.4 LRRK2 Domain Structure . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.4.1 Leucine rich repeat (LRR) domain . . . . . . . . . . . . . . . . . . 5
1.4.2 Ras of complex protein (Roc) domain and C-terminal of Roc
(COR) domain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.4.3 Mitogen-activated protein kinase kinase kinase (MAPKKK) domain 6
1.4.4 WD40 domain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.5 Mutations associated with PD in LRRK2 . . . . . . . . . . . . . . . . . . 7
1.6 Animal models of LRRK2 Parkinsonism . . . . . . . . . . . . . . . . . . . 8
1.7 D.melanogaster as a PD model . . . . . . . . . . . . . . . . . . . . . . . . 8
1.8 Mass spectrometry based proteomics . . . . . . . . . . . . . . . . . . . . . 9
1.9 Quantitative approaches in MS based proteomics . . . . . . . . . . . . . . 11
1.9.1 Stable isotope labeling approach . . . . . . . . . . . . . . . . . . . 12
1.9.2 Label-free approaches . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.10 Phosphoproteomics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
1.10.1 Strong cation exchange (SCX) . . . . . . . . . . . . . . . . . . . . 14
1.10.2 TiO2 enrichment . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
1.11 Mass spectrometric instrumentation . . . . . . . . . . . . . . . . . . . . . 14
vi
Contents vii
1.11.1 Gentle ionization methods . . . . . . . . . . . . . . . . . . . . . . . 15
1.11.2 Mass analyzers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
1.11.3 Ion trap . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
1.11.4 The Orbitrap analyzer . . . . . . . . . . . . . . . . . . . . . . . . . 18
1.12 Orbitrap in a hybrid instrument . . . . . . . . . . . . . . . . . . . . . . . 20
1.12.1 Orbitrap Velos . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
1.12.2 Q-Exactive . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
1.13 Aim of the thesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2 Material and methods 23
2.1 Drosophila Stocks and Harvesting . . . . . . . . . . . . . . . . . . . . . . 23
2.1.1 Generation of Human LRRK2, mutant LRRK2 (R1441C) Trans-
genic flies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.1.2 Drosophila lines . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.1.3 Generation of SILAC flies . . . . . . . . . . . . . . . . . . . . . . . 24
2.2 Survival Curve . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.3 Climbing Assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.4 Immunostaining and quantification of DA neurons . . . . . . . . . . . . . 25
2.5 Chemical and Material used for Proteomics Experiment . . . . . . . . . . 26
2.5.1 In-solution digest . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.5.2 In-gel digestion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.6 Immunoprecipitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2.7 Western blot analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.8 Immunocytochemistry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.9 Sample preparation for phosphoproteome . . . . . . . . . . . . . . . . . . 32
2.10 Liquid chromatography configuration . . . . . . . . . . . . . . . . . . . . . 34
2.11 Mass spectrometry configuration . . . . . . . . . . . . . . . . . . . . . . . 34
2.12 Proteomic Data Processing . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.12.1 Data Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.12.2 Identification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.12.3 Quantification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.13 Quantify the localization of phosphate group . . . . . . . . . . . . . . . . 37
2.14 Bioinformatic analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
2.15 In vitro phosphorylation assay . . . . . . . . . . . . . . . . . . . . . . . . 38
3 Results 40
3.1 Overexpression of Human LRRK2 (R1441C) induces Parkinsonism phe-
notypes in Drosophila . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
3.1.1 Transgenic human LRRK2 (R1441C) Drosophila . . . . . . . . . . 40
3.1.2 Overexpression of hLRRK2 (R1441C) in the retina results in de-
generation of photoreceptors . . . . . . . . . . . . . . . . . . . . . 41
3.1.3 Early mortality and locomotion disability in ddc-Gal4 driven hLRRK2
and hLRRK2 (R1441C) strains . . . . . . . . . . . . . . . . . . . . 42
3.1.4 hLRRK2 (R1441C) causes reduced tyrosine hydroxylase enzyme
in a subpopulation of DA neurons . . . . . . . . . . . . . . . . . . 43
3.1.5 Ectopic overexpression of hLRRK2 (R1441C) in all neurons in-
duces late-onset mortality and late-onset locomotion impairment . 45
3.2 Alpha sy-nuclein (αS) A30P and A53T Drosophila model of PD . . . . . 46
Contents viii
3.3 Quantitative proteome analysis of transgenic flies with stable isotope la-
beling in living flies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.3.1 Generation of SILAC fly and their labeling efficiency . . . . . . . . 47
3.3.2 Metabolic labeling does not change the proteome expression of
D.melanogaster . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
3.4 SILAC protein quantification in flies overexpressing hLRRK2 and hLRRK2
(R1441C) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
3.4.1 Transgenic hLRRK2 (R1441C) flies showed age-depending protein
changes in brain tissue compared to the overexpression of hLRRK2 53
3.4.2 Validation of selected candidates from proteome data . . . . . . . 58
3.4.3 Protein interaction of differiantilly expressed proteins of transgenic
hLRRK2 (R1441C) flies map illustrates strong intermolecular con-
nection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
3.5 Proteome expression of αS Drosophila model of PD . . . . . . . . . . . . 61
3.6 Transgenic hLRRK2 and αS flies show common and distinct age-dependent
protein changes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
3.7 Quantitative proteomics of A30P-αSDrosophilamodel of PD at presymp-
tomatic stage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
3.8 Quantitative proteomics of A53T-αS Drosophila model of PD at presymp-
tomatic stage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
3.9 Phosphoproteome analysis of hLRRK2 (R1441C) transgenic flies . . . . . 69
3.9.1 Global phosphoproteome analysis of hLRRK2 (R1441C) mutant
flies in PD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
3.9.2 In− vitro kinase assay revealed increased human Synj1 phospho-
rylation by hLRRK2 (R1441C) compared to hLRRK2 . . . . . . . 73
3.10 Immunoprecipitaion of hLRRK2 in Drosophila brain revealed several
synaptic proteins as potential interaction partners . . . . . . . . . . . . . 78
4 Discussion 80
4.1 Quantitative proteome analysis of hLRRK2 (R1441C) overexpressing flies
revealed specific changes related to PD . . . . . . . . . . . . . . . . . . . . 83
4.2 LRRK2 overexpression affects several cellular compartments . . . . . . . 84
4.2.1 Mitochondrial disruption in LRRK2 (R1441C) expressing flies . . 85
4.2.2 Synaptic vesicle proteins are regulated by LRRK2 (R1441C) . . . 85
4.3 The proteome changes in αS PD model flies . . . . . . . . . . . . . . . . . 86
4.4 Phosphoproteome dynamics and hLRRK2 interaction partners in a PD
model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
4.5 The functional relevance between SV trafficking dysfunction and DA de-
generation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
Bibliography 92
List of Figures
1.1 Nirgostiatal pathways . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.2 LRRK2 domain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.3 GTPase cycle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.4 Shotgun proteomics workflow . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.5 The labeling strategies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
1.6 Soft ionization methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
1.7 Ion trap . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
1.8 Orbitrap . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
1.9 Orbitrap instrument . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
3.1 hLRRK2 expression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
3.2 Retinal degeneration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.3 Surviving and climbing essay . . . . . . . . . . . . . . . . . . . . . . . . . 43
3.4 Dopaminergic degeneration . . . . . . . . . . . . . . . . . . . . . . . . . . 44
3.5 climbing disability and surviving essay . . . . . . . . . . . . . . . . . . . . 45
3.6 αS PD model phenotypes . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
3.7 SILAC fly labeling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
3.8 Ratio distribution of SILAC fly . . . . . . . . . . . . . . . . . . . . . . . . 49
3.9 Experimental workflow for quantitative . . . . . . . . . . . . . . . . . . . 50
3.10 Global proteome changes in hLRRK2 flies . . . . . . . . . . . . . . . . . . 51
3.11 Number of quantified proteins . . . . . . . . . . . . . . . . . . . . . . . . . 52
3.12 Correlation clustering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
3.13 Clustering and fisher exact test . . . . . . . . . . . . . . . . . . . . . . . . 54
3.14 Reproducible quantification . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.15 List of significant candidates . . . . . . . . . . . . . . . . . . . . . . . . . . 56
3.16 Retinal degeneration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
3.17 Validation of proteomics data . . . . . . . . . . . . . . . . . . . . . . . . . 59
3.18 Validation of proteomics data by Immunocytochemistry . . . . . . . . . . 60
3.19 Interaction networks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.20 Global proteome changes in αS flies . . . . . . . . . . . . . . . . . . . . . 62
3.21 Hierarchical clustering for transgenic flies . . . . . . . . . . . . . . . . . . 64
3.22 Comparison between transgenic flies . . . . . . . . . . . . . . . . . . . . . 65
3.23 List of significant genes in transgenic flies . . . . . . . . . . . . . . . . . . 65
3.24 Global phosphoproteome changes . . . . . . . . . . . . . . . . . . . . . . . 69
3.25 Reproducible phosphoproteome data . . . . . . . . . . . . . . . . . . . . . 71
3.26 Phosphoproteome changes in hLRRK2 flies . . . . . . . . . . . . . . . . . 72
3.27 MS spectra for phosphorylated candidates . . . . . . . . . . . . . . . . . . 73
3.28 Sequence allignment of significant candidates . . . . . . . . . . . . . . . . 74
ix
List of Figures x
3.29 LRRK2 phosphorylates synaptojanin . . . . . . . . . . . . . . . . . . . . . 75
3.30 LRRK2 autophosphorylation . . . . . . . . . . . . . . . . . . . . . . . . . 77
3.31 hLRRK2 interaction partners in Drosophila . . . . . . . . . . . . . . . . . 79
4.1 Schematic representation of vesicle trafficking at a DA synapse . . . . . . 91
List of Tables
2.1 The list of constructs name and genotypes . . . . . . . . . . . . . . . . . . 24
2.2 Material and chemical used for immunocytochemistry . . . . . . . . . . . 26
2.3 Material and chemical used for Protein quantification . . . . . . . . . . . 27
2.4 Material and chemical used for Proteomics . . . . . . . . . . . . . . . . . . 27
2.5 SDS-page materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
2.6 Material and chemical used for immuneprecipitation . . . . . . . . . . . . 30
2.7 Instrument and chemical used for Western Blot . . . . . . . . . . . . . . . 31
2.8 Material and chemical used for Phosphoroteomics . . . . . . . . . . . . . . 33
2.9 Instrument and chemical used for Mass-spectrometry . . . . . . . . . . . . 35
2.10 Used software . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.11 Kinase assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3.1 Significantly regulated proteins between 10 days old A3oP and αS flies . 66
3.2 Significantly regulated proteins between 10 days old A53T and αS flies . 68
3.3 Potential interacting partner of hLRRK2 in Drosophila . . . . . . . . . . 79
xi
Abbreviations
PD Parkinson’s Disease
DA Dopaminergic
SNpc Substantial Nigra Pars Compacta
TH Tyrosine Hydroxylase
αS Alpha Synuclein
LRRK2 Leucine Rich Repeat Kinase
ROC Ras Of Complex
COR C terminal Of Roc
MAPKKK Mitogen Activated Protein Kinase Kinase Kinase
GEFs Guanine Nucleotide Exchange Factors
GAPs GTPase Activating Proteins
SV Synaptic Vesicle
MS Mass Spectrometry
CID Collision Induced Dissociation
HCD Higher energy Collisional Dissociation
ETD Electron Transfer Dissociation
SILAC Stable Isotope Labeling of Amino acid in Cell culture
LFQ Label Free Quantification
SCX Strong Cation Xchange
ESI Electro Spray Ionization
MALDI Matrix Assisted Laser Desorption Ionization
LTQ Linear Trap Quadropole
FDR False Discovery Rate
xii
Dedicated to my parents
xiii
Chapter 1
Introduction
1.1 Parkinson’s disease (PD)
Parkinson’s disease (PD) is the second most prevalent age-associated progressive, neu-
rodegenerative movement disorder after Alzheimer’s disease and affecting approximately
1 % of the population over 55 years of age [1]. PD was first described in 1817 by James
Parkinson (1755-1824), the British physician, in his landmark publication called “An
Essay on the Shaking Palsy” [2]. However, it was Jean Martin Charcot (1825-1893)
who defined the syndrome and attributed the disorder as PD. Later on, Carlsson ac-
celerated the pace of PD discoveries by identifying dopamine in the mammalian brain
[3]. Although enormous advancement was made over the last 200 years to understand
PD neurobiology, still there is no accurate diagnostic tool and remedy for this disorder.
It is estimated that currently 6 million people around the world are affected by PD
and interestingly, men suffer more frequently than women [4]. The PD prevalence was
approximately 8334/100,000 in Germany [5] and the number is increasing due to the
increased average age of the whole German population.
1.2 PD Features
Neuropathologically, nigrostriatal dopaminergic (DA) neurons loss in the substantia ni-
gra and the presence of intracytoplasmic Lewy bodies in the remaining neurons are the
two key hallmarks of the PD brain. Frederic Lewy (1885-1950) first discovered the pres-
ence of intraneuronal inclusions in the PD brain and termed it Lewy bodies in 1912 [6–8].
The cytoplasmic nigrostrital pathway is described as one of the most major dopamine
pathways composed of DA neurons in substantial nigra pars compacta (SNpc) in the
brain that is involved in controlling voluntary movement. Striatum and basal ganlia
1
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gets the projection from SNpc through domapniergic neurons and PD causes significant
dopamine reduction in the putamen and less significant dopamine reduction in the cau-
date nucleus, see 1.1. [9–11].
Figure 1.1: Schematic representation of the human nirgostiatal pathways. Sriatum
is composed of putamen and caudate nucleus. A) putamen and caudate nucleus get
normal projection from SNpc in a healthy brain. B) PD patients get less projection
due to significant reduction of dopamine in putamen.
However, Braak and colleagues discovered progressive neurodegeneration also in the
cerebral cortex and olfactory bulb at different stages of PD [12]. In addition to these
pathological features of PD, there are some clinical features, namely, motor symptoms
and non motor symptoms [13]. The motor symptoms of PD are resting tremor, rigidity,
bradykinesia (slowness of movement) and postural rigidity and these are the result of
DA degeneration in SNPc. Among the four motor symptoms, resting tremor is the
most common symptom with 70 % of all PD patients. Nevertheless, PD patients may
suffer from other motor symptoms such as gait and posture disturbance, decreased arm
swing, masked face (hypomania), cramped handwriting (micrographia) and sustained
muscle contractions (dystonia). Besides motor symptoms, individuals with PD also show
varieties of non-motor symptoms which contribute significantly to PD morbidity. Mood
disturbance is the most common non-motor symptom where 20-80 % patients suffer with
depression [14]. Furthermore, patients may suffer with a range of cognitive disturbances,
including impulse control, subjective awareness and difficulties in allocation of attention
[15]. Dementia also occurs in PD patients, which cause slowing of thought, memory and
behavioral regulation [16, 17]. Taken together, broad-based management is required for
PD and there is no satisfactory cure for this chronic disorder.
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1.3 Risk factors and Genes Association of PD
Although the exact cause of PD is still unknown in most of the cases, there is still a
wide range of factors in PD contributing to nigrostriatal dysfunction. These are increas-
ing age, environmental factors and genetic mutations in selected genes. Among all risk
factors, age is the most common and 1-5 % of people of in 65-85 years age suffer from
this complex disease [9]. Environmental factors are also considered as a prominent cause
of PD in 1980 by discovering the fact that methyl-4-phenyl-1,2,3,6- tetrahydropyridine
(MPTP) can also induce levodopa-responsive parkinsonism [18].
However, approximately 5-10 % of PD cases are termed familial PD and thought to be
caused by genetic variation in selected genes. The percentage of these familial PD cases
can be even higher for specific groups of patients selected for age of onset, positive fam-
ily history and ethnic origin [19–21]. Recent ground breaking discoveries indicate that
mutations in at least six genes positively induce familial PD including two autosomal
dominant genes (αS and leucime rich repeat kinase 2) and three autosomal recessive
genes such as parkin, Dj-1 and PINK1 [22]. Though mutation in the genes only repre-
sents the case in small groups of PD patients, studies of these genes highlight several
pathways involved in sporadic PD pathogenesis, including protein aggregation, mito-
chondrial dysfunction, oxidative stress and ubiquitin-proteasome system defects [23–25].
Therefore, investigating the molecular mechanism of these PD genes may shed light on
the underlying causes of both familial and sporadic PD.
1.3.1 Alpha-synuclein
The mutation in the αS gene (PARK1 and PARK2) was first discovered in 1997 as a
causative factor for PD [26]. It was the first locus for autosomal dominantly inherited
parkinsonism and was identified at the chromosomal location 4q21 [27, 28]. αS is known
as the primary component of Lewy bodies (LBs) in PD patients [29]. Furthermore,
three mutations such as A30P, E46K and A53T have been found as contributors to PD
development [27, 28, 30, 31].
1.3.2 Parkin, PINK1, DJ-1, UCH-L1
Parkin (PARK2) is another known PD-linked gene causing a loss-of-function. Parkin
contributes to autosomal recessive juvenile parkinsonism (AR-JP) [32]. In total, 25 point
mutations have been found in the parkin gene which were reported to be linked with AR-
JP. In contrast to both sporadic and familial PD, the brains of most AR-JP patients lack
LB pathology [32]. Therefore, DA degeneration due to the AR-JP linked parkinsonism
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might reflects different cellular pathways for degeneration compared with other PD cases.
PINK1 is a mitochondrial serine/threonine kinase [33–36]. Mutations in PINK1 were
found in Europe, North America and Asian families.Though little is known about this
protein, PINK1 is reported to be linked with the maintenance of mitochondrial mem-
brane potential [37]. Mutation in DJ-1 is rare in PD and was first discovered in 2003 to
cause early-onset autosomal-recessive PD [38]. It is localized in both glial and neuronal
cells in the brain [39] and appears to function as an antioxidant [40]. UCH-L1 was first
identified in a sibling pair with autosomal-dominant PD in 1998 [41], however, this is
an extremely rare PD scenario to date [42, 43]. It is a neuronal specific protein that
hydrolyzes polymeric ubiquitin chains into monomers [44, 45].
1.3.3 Leucine-rich repeat kinase 2 ( LRRK2; PARK8)
PARK8 was first identified in 2004 in autosomal dominant PD linked to the PARK8
locus. The locus located within the chromosomal position 12q12 was first mapped in
a large Japanese family [46]. However, PARK8 linked parkinsonism was also found in
several European family, which shows its relative significance. The gene linked with
this PARK8 locus is called LRRK2 [47–49]. LRRK2 was reported as the cause of both
late-onset autosomal dominant familial PD, one of the most common forms of familial
PD and sporadic PD . The LRRK2 gene is a big gene with 2527 amino acids and spans
144-kB genomic region with 51 exons. It conserves multiple independent domains, see
1.2, suggesting its complex cellular function and regulation [47, 49]. Since the molecular
role of hLRRK2 in PD progression is the aim of this study, the study of LRRK2 domain
structures will be of particular importance to understand the complex and multi cellular
function.
Figure 1.2: Schematic view of LRRK2 domain structure. It cotains four domains,
namely, LRR, ROC, COR, MAPKKK and WD40 domain.
1.4 LRRK2 Domain Structure
LRRK2 is classified as a member of the ROCO protein family by the presence of 200-
250 amino acids Ras complex (Roc) followed by a 300-400 amino acid domain called
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COR ( C terminal of Roc) [50]. Sequence analysis has showed few independent domains
such as leucine rich repeat (LRR) domain, Roc domain followed by Cor domain, a
mitogen activated protein kinase kinase kinase (MAPKKK) domain and C terminal
WD40 domain in LRRK2 [51]. LRRK2 protein may serve as a scaffold for the assembly
of a multi-protein signaling complex since it has both protein interaction domains (LRR
and WD40) and enzymatic domains (Roc and MAPKKK).
1.4.1 Leucine rich repeat (LRR) domain
LRRK2 has 13 LRRs that are generally 20-29 residue long and contain sequence motif
(LxxLxLxxN/CxL). The primary function of this motif might be to provide a versa-
tile structural framework for protein protein interactions. However, this domain is also
associated with several biological mechanisms including cell adhesion, cellular traffick-
ing, neuronal development, cell polarization, apoptosis, gene regulation and cytoskeletal
dynamics [51].
1.4.2 Ras of complex protein (Roc) domain and C-terminal of Roc
(COR) domain
The Roc domain is classified as a member of ROCO family which conserves a separate
monophyletic group of the Ras superfamily of small GTPases [52]. Ras-related GTPases
are known as a molecular switch to regulate a variety of cellular functions by controlling
the GTPase cycle. This cycle consist of two different conformation; active (GTP-bound)
and inactive (GDP-bound).
The conversion between GDP to the GTP-bound is catalyzed by guanine nucleotide
exchange factors (GEFs) and controls the downstream signaling. However, GTP to
GDP-bound state is facilitated by intrinsic GTP hydrolysis. This process is acceler-
ated by GTPase-activating proteins (GAPs) in order to terminate the signaling [53].
The diverse cellular functions are regulated by the interaction between the GTP-bound
form and effector molecules. However, GDP-bound form interacts with GDP dissocia-
tion inhibitors (GDIs). The COR domain is a common feature of all ROCO proteins
which always link with the Roc domain. It contains 300-400 amino acids. This (Roc-
COR) domain pair has been conserved throughout evolution which reflects a functional
interdependence on each other.
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Figure 1.3: The GTPase cycle.
1.4.3 Mitogen-activated protein kinase kinase kinase (MAPKKK) do-
main
The kinase domain (MAPKKK domain) of LRRK2 has sequence similarity with the tyro-
sine kinase-like (TKL) subfamily of human protein kinases. Members of this family also
conserve sequence similarity to both serine/threonine and tyrosine kinases (J144). The
MAPKKK domain of LRRK2 resembles receptor interacting protein kinases (RIPKs)
which are the key players to activate mitogen-activated protein kinase (MAPK) path-
ways and sensors for cellular stress. Extracellular signal-regulated kinase (ERK), c-Jun
amino terminal kinase (JNK) and p38 MAPK are the three best characterized MAPKs
[54]. MAPK pathways are activated through diverse extracellular stimuli and these
pathways are three –tiered cascades comprising a MAPK kinase kinase, a MAPKK and
a MAPK where each kinase of MAPK pathways activates the successive kinase through
activation-loop phosphorylation. The majority of the active protein kinases need the
phosphorylation of the activation segment which enables substrate access and cataly-
sis to take place. The PD associated LRRK2 mutation G2019S lies at the N-terminal
boundary of the activation segment and is known to augment LRRK2 kinase activity
[55]. However, mutation (R1441C) in the ROC domain has been also reported to be as-
sociated with enhance kinase activity compared with wild type LRRK2 [56, 57]. Recent
studies indicate that the LRRK2 has the capability to self-associate and autophospho-
rylate in− vitro, although the autophosphorylated sites and their interdependence are
still unknown [58].
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1.4.4 WD40 domain
LRRK2 has seven WD40 repeats where WD repeat generally contains a GH dipeptide
11-12 residues at N-terminus and a WD dipeptide at the C terminus [52]. A number
of eurkaryotic proteins also has WD40 domain and these proteins are associated with a
wide variety of functions such as signal transduction, RNA processing, transcriptional
regulation, cytoskeletal assembly, regulation of vesicle formation and vesicular trafficking
[59]. However, the WD40 domains most likely facilitate the protein-protein interactions
in all these processes.
The development and pathogenesis of PD has been dynamically explored through the
understanding of parkinsonism genetics, since genetics might play a significant role in the
pathogenesis of PD. Studying LRRK2 will be of particular significance since mutations
in this PD gene are the leading cause of both autosomal dominant forms of PD and
sporadic.
1.5 Mutations associated with PD in LRRK2
Since familial PD cases have been reported to be linked with LRRK2 mutations, an ex-
tensive effort has been devoted to investigate the mutations of the LRRK2 gene in order
to understand the potential mechanisms of PD. Up to now, p.G2019S, p.R1441C/G/H,
p.Y1699C, p.I2020T and p.N143H are the established dominant inherited PD associated
mutations in LRRK2 [61]. Among them, the G2019S and R1441C are the most common
and were identified in several groups as a cause of both familial and sporadic PD [62].
For an example, G2019S contributes to 1-7 % of familial cases of parkinsonism of Euro-
pean and US origin and 1-3 % of sporadic PD [63]. However, R1441C mutations, located
in Roc domain, were initially identified in several families and in some cases, R1441C
mutation is more frequent than G2019S mutation in PD patients in some regions for ex-
ample, in southern Italy. Another study reporting 60 European families with autosomal
PD found a prevalence of 3.4 % for the R1441C mutation [64]. Some patients with the
R1441C mutation had classic αS positive Lewy body and Lewy neurite pathology, some
had tau pathology and others had asymmetric ubiquitin-positive inclusions [47]. In ad-
dition to these mutations, there are two missense variants ( R1628P and G2385R) which
are linked with susceptibility to PD in Han Chinese and East-Asians [61] and patients
with the Y1699C mutation displayed dementia and amyotrophy [47, 65]. The DA de-
generation of SNpc are not solely restricted to patients with both Y1699C and R1441C
mutations, since PET scan analysis showed these two mutations are indistinguishable
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from that of sporadic PD despite the pathological heterogenety [66]. These dynamic
pathologies associated with LRRK2 mutations might reflect that this protein is involved
in multiple cellular processes in neurons. Despite the known association between LRRK2
mutations and PD phenotypes, little is known about the molecular mechanisms of these
mutated LRRK2 genes and their interaction in cells. Therefore, genetic analysis, based
on animal models, might offer the promise to decipher underlying molecular bases of
PD.
1.6 Animal models of LRRK2 Parkinsonism
Animal models have been widely used in the research of PD genes. For example, overex-
pression of LRRK2 leads to DA degeneration in C.elegans. These transgenic C.elegans
showed longer lifespan compared with G2019S or nontransgenic age matched controls
[67, 68].
Other models, such as transgenic mouse model are potentially not robust since they
show only mild PD phenotypes. Transgenic mice, generated by using bacterial artificial
chromosome (BAC), expressing LRRK2 or LRRK2 with R1441G or G2019S mutations
showed minimal evidence of neurodegeneration [69]. Furthermore, making conditional
expression of WT or transgenic G2019S LRRK2 mice through the calcium/calmodulin-
dependent protein kinase II (CamK II) promotor also failed to induce DA neuronal
degeneration [70]. However, the current LRRK2 transgenic mice showed nigrostriatal
system impairment such as decreased dopamine release and behavioral deficits [61].
In contrast to vertebrate models, Drosophila PD models based on various form of PD-
linked genes have been developed to understand their molecular function and how their
dysfunction causes PD. For example, overexpression of both αS and LRRK2 mutated
genes in Drosophila showed severe PD phenotypes including age dependent locomotor
disability and DA degeneration [71–74]. Although there are physical differences between
Drosophila and human, there is a remarkable degree of conservation in their funda-
mental biological pathways [75]. Thus, Drosophila offers a potential value of function
analysis of human disease.
1.7 D.melanogaster as a PD model
D.melanogaster, commonly known as the fruit fly, is an excellent model organism for
studying neurodegenerative diseases such as PD, Alzheimer’s disease and Huntington’s
disease due to the following facts: it has short life span which is useful for scientist in
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modeling neurodegenerative disease and secondly, it has DA system which partly resem-
bles the human DA system. Furthermore, Drosophila culturing is cost effective and easy
to handle in the laboratory. In addition, it has well characterized anatomy and a com-
pletely sequenced genome [76, 77]. There exists powerful genetic techniques developed
by Drosophila researchers to make full use of the model [78]. For example, human neu-
rodegenerative disease associated genes can be introduced into the Drosophila genome
via the binary yeast transcriptional co-activator GAL4 and upstream activting sequence
(UAS) system [79]. In addition, Drosophila contains 44% homologous sequences
with humans [80] and approximately 77% of the genes are known to be associated with
hereditary human disorders have Drosophila homologues including, parkin and DJ-1
[80]. Moreover, Drosophila has a complex central nervous system which makes it possi-
ble for PD researchers to explore large scale pharmaceutical screens [81]. In last decade,
researchers generated various PD models in Drosophila, based on PD-associated genes,
in order to understand the biological functions and how their dysfunction might lead to
PD. In this study, we have chosen Drosophila PD models based on the two most inten-
sively studied genes, LRRK2 and αS, in order to elucidate their fundamental molecular
mechanism underlying PD.
1.8 Mass spectrometry based proteomics
The term proteomics defines the large-scale study of the whole complement of an organ-
isms proteins. Mass spectrometry (MS) based proteomics is already a well-established
powerful approach for studying biological process in health and diseases [84–86]. Several
key features such as, unbiased identification of proteins and protein modifications from
complex biological mixtures showed the robustness of this technique and the strength
in understanding protein dynamics, protein-protein interactions and post translational
modifications. In the discovery approach, proteomics is performed to identify the pro-
teins in an assumption free manner. On the other hand, the targeted approach focuses
only on some subsets proteome. Now a days, MS based proteomics has made it possible
to identify several thousand proteins from complex mixtures and explore protein-protein
interactions, mapping of post-translational modifications with confidence [87–90].MS
based proteomics approaches might be classified into two major groups, namely top-
down and bottom-up. In the top-down approach, ionized proteins are identified by the
mass spectrometer by determining their intact and fragment mass-to-charge rations.
This approach has some severe technical limitation of the complex protein mixture
analysis since complex mixtures have a dynamic protein mass range, which might be
challenging to solubilize and to separate from each other before measurement. However,
the bottom-up approach, often referred to as shotgun proteomics, is performed with
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proteins separation and digestion into peptides prior to MS analysis. Since ionization
efficiency of peptides is better than proteins, it produces less complicated spectra which
are easier to interpret. Therefore, this approach outlawed all the limitations of the top-
down approach. Figure 1.4 represents the schematic workflow for the classical shotgun
proteomics. Briefly, shotgun proteomics is performed with proteins mixtures derived
from cells or tissue sample complexity is reduced by performing gel based methods, size
exclusion or ion-exchange chromatography [91].
Figure 1.4: Proteins mixtures are separated (optional) and digested into peptides
during the sample preparation and peptides are fractionated by nanoscale chromatog-
raphy followed by transferring the peptides by electrospray ionization into the mass
spectrometer. Masses of the intact and fragmented peptides are measured in mass
spectrometer. Finally, proteins are identified through database search and significant
candidates are determind by statistical analysis.
Certain biochemical procedures are performed to digest proteins into shorter peptides.
Trypsin and lysC are the most frequently used enzyme due to their high specificity to
ariginine / lysine [92]. However, some other enzymes, namely, GluC, AspN or LysN are
also useful to increase deep protein sequence coverage depending on proteomics contexts
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[89]. Currently, various protein digestion protocols such as, in solution, in gel and the
filter-aided sample preparation (FASP) are being followed based on different samples
[93]. Since, the digested peptide mixture is potentially complex, the peptide separa-
tion is executed by using liquid-chromatoraphy. The peptides binds with c18 material
of a chromatography column at low pH by adding formic or acidic acid to samples.
Furthermore, optimum gradient separation and column dimension are also important
for shotgun proteomics to gain deep mass spectrometric analysis and less analytical
problems respectively [94]. Separated peptides are directly sprayed in the mass spec-
trometer through electrospray ionization. The mass spectrometer measures the intact
masses of peptides (MS1 scan, precursor mass) followed by fragmenting selected pep-
tides for measurement (MS2 scan). Peptide fragmentation can be achieved by applying
different methods such as collision induced dissociation (CID), higher energy collisional
dissociation (HCD), electron transfer dissociation (ETD) and a ladder is created by the
fragmentation to directly derive the amino acid sequence. Theoretical mass of a peptide
is compared with intact and fragmented peptide mass by a search engine (Mascot or
Andromeda) which performs a database search [95]. However, statistical algorithms are
highly required for the best match in a database search, since most of the spectra hold
only partial sequence information. Identified peptides are accumulated in order to pro-
vide protein information and significant proteins are highlighted by statistical analysis.
1.9 Quantitative approaches in MS based proteomics
In the last decade, MS-based proteomics have emerged as a robust and powerful tech-
nique for biological research to identify many proteins from complex mixtures in a rel-
atively short time frame. Although the protein identification from various biological
samples is important, it often requires the knowledge of protein amount, their changes
and posttranslational modifications under different circumstances. Since the signal in-
tensities from MS do not represent the peptide concentration solely due to the behavior
of the peptides during ionization, quantitative information cannot be achieved by MS
approach. Therefore, it was a prerequisite to develop the strategies in order to have
the quantitative information by relative quantification (protein abundance difference
between two samples) and absolute quantification (determine copy number per cell).
The quantitative information can be achieved by applying two basic strategies, namely
label free approach and stable isotope labeling approach, see 1.5.
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1.9.1 Stable isotope labeling approach
The principle of stable isotope labeling is based on introducing a defined stable isotope in
a sample which results in distinguishable spectra due to the mass difference with another
sample. This approach allows to mix different labeled samples together to measure their
relative abundance. Since labeled samples are introduced in the different stages and are
measured together, the quantification accuracy is increased due to having less biological
variability. The metabolic labeling approach introduces a non-radioactive isotope in
the growth medium, food, or by replacing an essential amino acid in the medium or
food with their heavy counterpart. The first approach, a global manner, replaces all
the nitrogen atoms with heavy nitrogen and produces broad isotope distributions which
are complicated to analyze [96]. Hence, it has some limited application in plants and
bacterial biology. In contrast, the second approach is defined as Stable isotope labeling
of amino acids in cell culture (SILAC). SILAC is a metabolic labeling approach used for
quantitative proteomics where relative changes in protein abundance are most accurately
measured by comparing the natural form of a peptide with its stable isotope labeled
homolog [97]. The most frequently used essential amino acids for SILAC are arginine
and lysine. Since trypsin or lysC protease cleaves the C–terminal to these amino acids,
peptide digestion with tripsin or lysC results in peptides containing at least one labeled
amino acid (ariginine or lysine). Therefore, every single peptide produces two isotope
clusters, SILAC pair and the intensities of the SILAC pair gives a SILAC ratio (a
reflection of an identified peptide). Although SILAC was introduced in cell culture at
the beginning [98], recently it has been extended in living animals like mice, zebra fishes,
C.elegan and flies [99–101].
1.9.2 Label-free approaches
Label free proteomics performs the quantification without applying the stable isotope
labeling. It is a simple, economical method that can be applied to any samples including
clinical samples. Although this approach is straight forward, it suffers with less accu-
racy, higher variability and requires complex statistical analysis due to sample prepa-
ration and separate measurement. However, label-free approaches are being improved
by introducing an intensity-based label-free quantification (LFQ) with the MaxQuant
software platform [103, 104] where the algorithm contains several normalization steps
in order to reduce experimentally introduced variability. Hence, this method has been
applied to relative quantification with increasing success [103].
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Figure 1.5: The labeling strategies and their impact on quantitative accuracy. The
schematic depicts a typical label-based and label-free workflows. The labeled samples
(colored boxes) can be distinguished in the mass spectrometer, however the unlabeled
samples (empty boxes) are not. The experimental error can be reduced if the samples
are pooled in the beginning [102].
1.10 Phosphoproteomics
Protein phosphorylation is one of the most significant post-translational modifications
(PTMs) which has a significant importance, especially in signal transduction as an ac-
tivating and deactivating switch for protein activity. During the later stages of signal
progression, it plays a prominent role in both signal attenuation and termination. Dis-
ruption of these controlled systems often leads to different diseases like neurodegenerative
disease, cancer [105–107] and hence, study of phosphoproteomics is of great importance.
Phosphorylation is known to occur in one third of the proteome, meaning they are typ-
ically of low abundance [108]. There are various methods which have been developed to
enrich the low abundant phosphorylated proteins or peptides and the chromatographic
methods are the most commonly used due to their high enrichment efficiency and ex-
perimental simplicity [109–113].
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1.10.1 Strong cation exchange (SCX)
SCX chromatography is a powerful approach for phosphorylated peptides enrichment,
which works based on the difference in the solution charge states of phosphorylated and
nonphosphorylated peptides. The typical tryptic peptides have a net charge of +2 at
pH 2.7 due to an N-terminal amino group and protonated C-terminal arginine or lysine
side chain and therefore, if a peptide is phosphorylated, the net positive charges will
be reduced due to having additional negatively charged phosphate groups. Therefore,
phosphopeptides can be enriched by SCX chromatography based on reduced positive
charges on the phosphorylated peptides. Furthermore, SCX chromatography can be
used to separate the peptides with different solution charge states on preparative or an
analytical column by using a linear salt gradient. Gygi and coworkers showed that +1
SCX fractions containing less than 3 % of the total tryptic digests were highly enriched
in phosphopeptides [114].
1.10.2 TiO2 enrichment
Titanium dioxide, TiO2, particles are used as the column packing material like silica-
based supports due to their chemical stability, rigidity and unique amphoteric ion-
exchange properties [115]. It has been demonstrated that TiO2 is capable to absorb
organic phosphates effectively in acidic conditions and desorb in alkyline conditions.
Therefore, TiO2 has the potentiality to enrich phosphopeptides. Heck and coworkers
reported the high enrichment efficiency (90%) of phosphopeptides in simple samples by
TiO2 chromatography [116]. However, this approach has some limitation for complex
as because the non-specific binding of acidic amino residues such as glutamic acid and
aspartic acid.
1.11 Mass spectrometric instrumentation
In general, any mass spectrometer requires three basic parts; an ion source, a mass
analyzer and a detector. Furthermore, it also has an inlet system (for ion source), data
system, vacuum system, and control electronics. The ion source ionizes the analytes
and transfers them to a mass spectrometer, which will be further manipulated inside the
instrument. The charged analytes flow to the mass analyzer due to pressure difference
and a series of electric potential difference. Since all the charged analytes have their
individual charge to mass ratio, they have different motion under an electromagnetic
field which helps to separate and analyze the ions. The ion separation and analysis in
the mass analyzer can be varied such as magnetic sector, time-of-flight, quadrupole, ion
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trap and Fourier transform cyclotron resonance analyzer. The ion signal is measured in
the detector and amplified to improve the signal and sensitivity for the instrument. The
data is viewed as a spectrum in the detection system. In the proteomics context, mass
to charge ratio represent the protein identity and the intensity signifies the abundance
of a protein [117]. A short review of mass spectrometry is discussed in the following
section.
1.11.1 Gentle ionization methods
Electron ionization, chemical and photo ionization used to be the common methods
for mass spectrometers. However, they had certain limitations for large and fragile
biomolecules because of their large biomolecule’s decomposing capability during the ion-
ization process which could lead to less informative spectra. Two groundbreaking gentle
ionization methods are known to open the era of mass spectrometry based proteomics
as these methods allowed for proteins to be brought into gas-phase without destroying
them, see 1.6. In the electrospray ionization (ESI) method, a small needle is utilized to
spray small droplets containing the charged sample molecules into a strong electric field
[118]. The solvents are evaporated and enter the mass spectrometer as desolvated ions
during the process. In contrast, matrix-assisted laser desorption ionization (MALDI)
approach employs a laser that excavates and ionizes molecules from a solid matrix. Al-
though both techniques are useful for the large biopolymer ionization, in principle they
are very different in terms of coupling to mass spectrometers. ESI method performs in
atmospheric pressure and produces ions in a continuous manner, in contrast, MALDI
works in the vacuum of the mass spectrometer.
1.11.2 Mass analyzers
The core element of every mass spectrometer is its mass analyzer. There are various kinds
of mass analyzers that exhibit unique characteristics, making them superior than others
for different tasks. The key parameters of a mass spectrometer are the mass precision,
mass accuracy, dynamic range, resolution, sensitivity, speed and fragmentation. The
term mass precision defines the “repeatability” which means the variation in several
measurements for the same mass and mass accuracy represent the deviation of the
measured mass from the theoretical mass [119]. Dynamic range, the strongest signal to
weak signal ratio, is a criterion for sampling deeply into a complex peptide mixture and
resolution, a dimensionless number calculated by dividing the mass of the observed peak
by its width, is important for proper quantification. Among various mass analyzers, two
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Figure 1.6: The schematic representation of soft ionization methods for biological
mass spectrometry. ESI method produces ion in continuous manner where as MALDI
generates singly charged ions. Adopted from [87].
most common mass analyzer such as, the linear ion trap and the orbitrap analyzers will
be discussed below.
1.11.3 Ion trap
The quadrupole ion trap mass analyzer was first pioneered by Wolfgang Paul [120]. It is
a very versatile mass analyzer in terms of mass selection, fragmentation and detection
and this mass analyzer can be either a 3D or linear ion trap. Wolfgang Paul and Hans
Georg Dehmelt shared the 1989 Nobel Prize in physics for their contributions to the
development of quadrupole and magnetic ion traps. The ion trap is often called Paul
traps, since the ion trap works based on Paul’s principle. The trap consists of four pre-
cisely parallel metal hyperbolic rods and each has three axial sections. The discrete DC
level of each section generates a potential well and traps ions in the axial direction [121].
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The opposite rods are connected, paired and the radio frequency is applied to the pair.
Therefore, one pair receives a positive and another pair a negative direct voltage (dc)
that is superimposed by a time-dependent radio frequency (rf) potential. The oscillating
electric field in the center of the quadrupole only allows a narrow mass-to-charge (m/z)
range to pass on a stable trajectory when the ions are injected into the quadrupole in
the direction of the rods and the leftover ions will be impinged on the rods. Hence, Only
ions of specific mass to charge ratios are allowed to go through the narrow m/z range
by ramping the rf and dc potential. In the ion trap instrument, ions can move in all
directions due to three dimensional electric field effect and the x-z motion of the ions
that go to the z direction can be described by the Mathieu equation, a second order
differential equation.
Figure 1.7: A) The schematic view of linear two dimensional ion trap mass analyzer.
B) Plots of the dimensionless parameters a and q for different m / z values generate
the stability diagram (adopted from [121]).
The solutions of this differential equation are two dimensionless parameters a and q
which represent the amplitude of the dc and rf current. The intersecting mass-scan
line (a/q constant) of the aq plot (stability diagram of quadrupole) provides the m/z
ratios that can pass through the quadrupole without interruption. In general, though
quadrupole mass analyzers are compact, it features a rather low mass resolution. In
principle, the higher resolution can be achieved by narrowing down the rods diameter,
increasing rf frequency and decreasing the acceleration potential of the ions. However,
considering both resolution and mass range, the quadrupole characteristics improvement
is challenging due to the substantial effort in manufacturing. For example, increasing
the length of the rods will improve the mass resolution by increasing the number of os-
cillations of the ions, however increasing the length of the rods is restricted by practical
limitations [95, 122–125]. Relatively high pressure in the range of 10−02 pa is required
for ion trap operation compared with other mass spectrometers and this high pressure
is achieved by the constant flow of inert gas (He) or nitrogen . The continuous flow of
gas slows down the fast moving ions and act like a cushion. Hence, it helps to improve
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Figure 1.8: The cross-sectional view of the Orbitrap mass analyzer. The black arrows
represent the radial (r) and axial (Z) directions. The orange arrow indicates the ion
movement. The ions move along the axis and around the central electrode ( Orange
shade). The the image current is detected in outer barrel electrode which is splited into
two electrically isolated halves (adopted from [129]).
the trapping efficiency and mass resolution. Taken together, ion trap has versatile capa-
bility including storing, isolating, fragmenting and detecting ions in combination with a
multiplier .
1.11.4 The Orbitrap analyzer
The Orbitrap mass analyzer was first described by Alexander Makarov in 2000 although
the basic design of the Orbitrap was based on Kingdon’s trap from 1920 [126–128].
The Kindon trap was operated in an electrostatic field where an electric potential was
applied between outer cylindrical electrode and an inner thin electrode (act as the central
electrode). However, the Orbitrap consists of two parts, namely, the inner spindle-like
central electrode and the outer barrel shaped electrode, see fig. 1.8. Since, the inner
space between these two electrodes are not constant in the z direction due to analyzer
configuration, the electric field also varies inside the analyzer. For example, the electric
field is weakest in the equator plane (the largest space between two electrodes) and
increases with the distance from the center. The ions are accumulated and stored in
C-trap before entering the Orbitrap cell. The C-trap is an RF-only quadrupole with a
shape of the letter “C”. Once ions enter into Orbitrap from the C-trap, the two forces
starts acting on the ions such as radial force and the axial force. The radial force is
generated by the radial field (Er) which attracts the ions towards the central electrode.
If the attraction force (centripetal force) and tangential velocity of the ions (centrifugal
force) is equal, the ion will have a circular trajectory orbit motion around the central
electrode an the initial energy of the ions determines the oscillation of the ions.
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In contrast, the axial field has a heterogeneous form, first, the field intensity varies
in the z direction in the opposite direction from the equator plane and second, the
direction of the electric field vector at different points that are not parallel to each other
along the z direction. The heterogeneous electric field generates a mass dependent ion
oscillation towards the z direction simultaneously to the circular motion around the
central electrode. Once ions are entered inside the analyzer, they are attracted towards
the equator plane and traverse it. However, when the ions are in the other half of the
Orbitrap cell, an opposite force pulls the ions back to the equator plane and these forces
increase with distance from the equator plane until the kinetic energy becomes zero in
the axial direction. Ions are then accelerated back to the equator plane and acquire
an axial oscillation. These combinations of axial and radial movement lead to a stable
spiral-like trajectory around the central electrode. The axial oscillation is independent
of the initial energy of the ion and oscillating frequency can measure the mass of the ions
directly (see equation). The equation below shows mass frequency correlation where ω
is the frequency in rad/s and k is the instrumental constant.
ω =
√
k
m
z
The Fourier transformation converts the frequency readout generated from the axial
oscillation of all ions into m/z spectrum. Since the frequency of the ions can be mea-
sured with very high precision, the Orbitrap mass analyzer achieves a very high resolv-
ing power. The ion trapping capacity of the Orbitrap is significantly higher than the
quadrupole ion trap and hence, posses much higher space charge tolerance. The Or-
bitrap mass accuracy requires very high vacuum in order to avoid the collisions with
background molecules which can lead the dephasing of ions and thus deterioration of
the mass accuracy and resolution. Therefore, ion activation through the collisions of
neutral gas molecules is not possible in this analyzer. However, the mass accuracy can
be further improved by doing a real time calibration with ions present in ambient air
[130]. In general, Orbitrap is coupled to into an ion selection and fragmentation devices
like ion trap or quadrupole or a dedicated collision cell, since it cannot perform the
fragmentation.
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1.12 Orbitrap in a hybrid instrument
Now a days, Orbitrap analyzer and linear ion trap are exclusively merged into mass spec-
trometers and commercially available by Thermo Fisher Scientific. These hybrid mass
spectrometers such as linear trap quadropole (LTQ) Orbitrap, Orbitrap Velos, Orbittrap
Elite, etc use the Orbitrap for high accuracy and precision recording of precursor masses
and HCD fragment masses although the rapid peptide fragmentation is performed by a
linear ion trap. However, the benchtop instrument like Q-Exactive has the Orbitrap as
a sole mass analyzer, which performs precursor recording as well as ions fragmentation.
The Orbitrap Velos and Q Exactive were used for all the measurements in this thesis
and therefore, these instruments will be introduced in more details.
1.12.1 Orbitrap Velos
The Orbitrap Velos has the similar principle design like the LTQ Orbitrap, the first
mass spectrometer that included an Orbitrap mass analyzer, however, there were several
improvements which made it even better mass spectrometer in terms of ions capturing,
trapping and fragmentation. The front part was radically modified by introducing S–lens
instead of the tube lens which provides better transmission of ions into the instrument
and hence, the sensitivity is increased [123]. Furthermore, the linear ion trap in LTQ
Orbitrap was replaced by a dual linear ion trap of the Orbitrap Velos. The first and sec-
ond ion traps are operated in high (5.0 x 10−3 Torr) and low (3.5 x 10−3 Torr) pressure
respectively and these allow very efficient trapping, isolation, fragmentation of ions and
mass spectra recording at higher speed . On the other hand, other developments, in-
cluding design (S-lens and C-trap HCD cell combination) and electronics provide higher
numbers of iron accumulation due to efficient ion transfer, which allows five to ten times
more ions per unit time into HCD cell and gives prominent HCD fragmentation for pro-
teomics experiments .
All the advantages such as rapid fragmentation, scanning in the ion trap or efficient
quadrupole like fragmentation in C-trap associated with high resolution mass analysis
in the Orbitrap instrument allows this Orbitrap Velos instrument two analysis strategies.
The high-low strategy allow high resolution and high mass accuracy of precursor masses
recording in the Orbitrap and the low resolution with a low mass accuracy of fragmented
ions in the linear ion trap. However, the high-high strategy uses the improved HCD set
up and high resolution, high mass accuracy of fragmented spectra in the Orbitrap.
Taken together, higher sensitivity and higher speed of the Orbitrap Velos offers efficient
shotgun proteomics experiments.
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Figure 1.9: The schematic representation of two Orbitrap family members. A) The
LTQ-Orbitrap Velos with its S-lens and dual ion trap with HCD. B) The Q Exactive,
a benchtop instrument, with its Orbitrap mass analyzer (adopted from [131]).
1.12.2 Q-Exactive
The Q Exactive is a bench top instrument and one of the most latest members of the
Orbitrap family. This bench top instrument allows to perform both precursor mass
detection and all ions fragmentation with an Orbitrap mass analyzer [132]. The Q-
Exactive has one of the most robust and mature mass filter which is capable of isolating
selected ions on a faster time scale. Although it operates only HCD fragmentation
mode, the speed and sensitivity of HCD are not limiting. The parallel filling of ions
combined with simultaneous ion selection and fragmentation results the execution of
top 10 method with 1−s cycle time [131]. It provides the high-high data from proteomics
measurements which resembles the HCD experiments with Orbitrap Velos. However, the
shorter ion path, lack of a linear ion trap, improved electronics, software and the applied
enhanced Fourier Transform (eFT) algorithm make the resolution of this instrument two
times higher than any of its predecessor mass spectrometers. In summary, Q Exactive is
one of the most robust and powerful mass spectrometer for shotgun proteomics, which
provide high quality mass spectrometric data for the scientific community .
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1.13 Aim of the thesis
As mentioned above, PD has been known for approximately two centuries, however the
fundamental mechanisms underlying DA neuron degeneration remains poorly under-
stood. So far about 20 LRRK2 mutations have been linked to PD and strikingly, gene
mutations in the leucine-rich repeat kinase 2 (LRRK2) are the most common cause of
autosomal dominant PD [52]. Recently, it has been shown that amino acid substitutions
within the kinase and GTPase domain of LRRK2 are closely associated with the onset of
PD [133]. However, direct targets of LRRK2 and its mutant forms are poorly described
in living animals and it has not yet been explored how mutations in different LRRK2
domains initiate degeneration of DA neurons. Concurrent data are only available for the
G2019S mutation which leads clearly to an increased kinase activity [134]. Likely, it has
been shown that amino acid substitutions at amino acid position 1441 (R1441C/G) de-
creases the GTPase activity leading to an elevated GTP binding capacity and enhanced
kinase activity [135]. However, other reports showed that the kinase activity of LRRK2
(R1441C/G) mutants is not affected [136].
Recent development in high-resolution MS-based proteomics has made it possible to
identify thousands of proteins from complex biological samples within a couple of hours.
In addition, MS-based phosphoproteomics is also enabled site-specific identification
of hundreds of thousands of in − vivo PTMs [90]. Therefore, high resolution mass
spectrometry-based technologies become a powerful tool to study different diseases at
the molecular level.
In the present study, we have chosen the fruitfly (Drosophila) as a model system to
investigate the consequences of overexpressing human LRRK2 (R1441C) in DA neurons.
We aimed to perform a global proteomics to study of PD progression in fly using SILAC
fly based in−vivo quantification at different disease stages. Since an important function
of LRRK2 is its kinase activity under regular and mutated conditions, we also aimed
performed a global phosphoproteome analysis to gain more insights into affected LRRK2-
dependent signaling pathways and direct LRRK2 targets. Taken together, we intended
to open a new window to address hLRRK2 (R1441C) mediated PD mechanisms that
might shed light on fundamental ethiology of PD.
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2.1 Drosophila Stocks and Harvesting
Drosophila stocks- AllDrosophila stocks were maintained on standard yeast-agar medium
with 250C ±1 and 12 h the light-dark cycle. The UAS/Gal4 system, a bipartite system,
was used for tissue specific expression of transgenes in flies. This system conserves two
components, namely, the UAS responder element and the Gal4 driver and it is only
active when both UAS responder and Gal4 driver are present in the same lineage [79].
In this study, several driver lines such as ddc-gal4 (Dopamine decarboxylase), GMR-gal4
(Glass multiple receptor), and elav-gal4 (embryonic lethal abnormal vision) were used
for tissue specific expression of UAS-hLRRK2 and R1441C mutant allele. The chromo-
somal location of transgenes was determined by using chromosome 2nd balancer (W1118;
Sco/Cyo; +/+) flies and 3rd balancer (W1118; +/+; TM3/TM6B) flies.
2.1.1 Generation of Human LRRK2, mutant LRRK2 (R1441C) Trans-
genic flies
The LRRK2 and its mutant (R1441C) allele were cloned into N-terminal FLAG-tagged
pPFW vector (Bloomington Drosophila Center) using Gateway technology from pDEST
vector using PDNR (Invitrogen) as shuttle vector. pDONR vectors are Gateway adapted
vectors designed to generate attL-flanked entry clones containing gene of interest follow-
ing recombination with an attB expression clone. Once an entry was created, hLRRK2
gene was shuttled into pPFW expression vectors using the Gateway LR recombina-
tion reaction. The positive clones containing the insert were identified by restriction
digestion and sequencing. The plasmids were sequenced by forward primer UASP
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5 GGCAAGGGTCGAGTCGATAG 3 and reverse primer K10 5TGGTGCTATGTT-
TATGGCGC 3. Plasmids were then microinjected to w118 embryos (Venedis Injec-
tion Services, Oslo, Norway). Thus, we got two transgenic lines, namely, UAS-LRRK2
and UAS-LRRK2 (R1441C). To obtain the DA expression of transgenes, virgin females
from ddc::GAL4 line was crossed with males from the UAS:LRRK2 and UAS-LRRK2
(R1441C) experimental flies. On the other hand, for pan neuronal expression, vir-
gin females from elav:: GAL4 line was crossed with males from the UAS:LRRK2 and
UAS-LRRK2 (R1441C) flies. Western blot analyses were performed to check LRRK2
expression level by using anti-FLAG. Transgenic flies ( 30 flies per vial) were transferred
to new vial in every third day. We collected 2000 flies of each genotype at day 1, 10 and
30 post-eclosion. Flies were anesthetized with CO2 and heads were collected on dry ice
followed by storing them at−800C for further use.
2.1.2 Drosophila lines
Control and all transgenic flies used in this study are presented below. The list of con-
structs name and genotype are presented below,see table 2.1.
Table 2.1: The list of constructs name and genotypes
No Construct name Genotype
1 White eyes W1118; +; +
2 Canton S +; +;+
3 ddc-Gal4 W1118; p(w+,ddc-Gal4.L]; +
4 elav-Gal4 W1118; p[w[+mc]=Gal4-elav.L]2/Cyo; +
5 UAS-hLRRK2 (Wt) W1118; p(w+,UAS-hLRRK2-wt]/Cyo; +
6 UAS-hRRL2 (R1441C) W1118; p(w+,UAS-hLRRK2-R1441C]/Cyo; +
7 UAS-HsapSNCA.F W*; PUAS-Hsap\SNCA.F5B;+
8 UAS-HsapSNCA.A53T W*; PUAS-Hsap\SNCA.A53T15.3;+
9 UAS-HsapSNCA.A30P W*; PUAS-Hsap\SNCA.A30P40.1;+
2.1.3 Generation of SILAC flies
D.melanogaster, Strain W1118, was cultured with standard method: 250C in 50-75%
humidity. However, we used house made (Silantes GmbH) SILAC food (H20 700 ml,
Agar 15 g, D(+)-Glucose anhydrous 50 g, Lys6 labeled Saccharomyces cerevisiae (S2886
TWY7) dry biomass 100 g, 30 ml 15% Nipagin solution) in a 12 h light-dark cycle
to generate Lys-6 labeled heavy flies. Initially autoclaved sterile small tube (25 mm
diameter) has been filled with 1-2 cm thick layer of medium. This corresponds to
approximately 0.3 g of lysine (6)-yeast. The adult flies are transferred in to tubes when
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the medium is being already cooled and hardened. The distribution of male and female
flies will always be a ratio of 1 (male): 3 (female) since a male is able to mate with
several females. In total, 20 flies were used for each vial to produce enough eggs on
SILAC food. Parent flies were transferred to new vial after 3-4 day in order to avoid the
mixing generation. After mating, the egg-laying begins on the yeast and within about
24 hours, the fertilized eggs develop into the first larval stage. The fully labeled adult
flies from F1 generation were collected at day 1, 10 and 30 post-eclosion and few SILAC
flies from F1 generation were taken for checking the labeling efficiency (≥ 96%) of heavy
Lysine-6 by Mass-spectrometry (MS).
2.2 Survival Curve
We chose 50 flies from each genotype in order to monitor the survival rates. Standardized
media and standard temperature 250C were maintained to grow the flies. Flies were
transferred to fresh food media in every 3 to 4 days. Dead flies were counted under the
microscope and to achieve survival curves, mortality was scored daily and analyzed by
using Kaplan-Meier survival curves. This experiment was repeated two times.
2.3 Climbing Assay
Locomotor ability of flies was tested by using a climbing assay (negative geoaxis assay)
as previously described [137, 138]. Briefly, cohorts of 60 flies from each genotype were
taken for the assay weekly from 1 week to 14 weeks. The age matched flies were selected
randomly, anesthetized with CO2 and followed by placing in a vertical plastic column
(length, 30 cm; diameter, 1.5 cm) as described previously [47, 139]. After a 60 min
recovery from anesthesia, flies were gently tapped to the bottom of the column. The
number of flies that could climb above the median line of the cylinder in 10 seconds were
counted and calculated in percentage. The climbing assay was repeated three times every
week, with independently derived transgenic lines. We found similar results from each
experiment.
2.4 Immunostaining and quantification of DA neurons
We executed Fluorescent immunostaining on whole-mount dissected adult brain at 1,
10, 30, and 45 days of age [140, 141]. Cohorts of six to eight flies per genotype were
selected for immunostaining at each time point. All dissected brains were fixed and
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TH positive neurons were stained as previously described [142]. Rabbit polyclonal anti-
TH (Milipore), and anti-Flag-antibodies (Sigma) were used as the primary antibodies.
For secondary antibodies, Alexa Fluor 488 goat anti-mouse IgG and Alexa Fluor 568
goat anti-mouse IgG (Invitrogen) were used for visualization. The stained brains were
mounted in mounted media (MOWIOL). Each brain was scanned using optical sec-
tion confocal microscopy (Zeiss LSM 510) and collected Z series images were projected
into a 3D animation to quantify the number of TH positive neurons in Drosophila brain.
Table 2.2: Material and chemical used for immunocytochemistry
Chemical Specification Company
Paraformaldehyde
Phosphate buffer pH 7.5
Sucrose
Ringer solution
Tissue-Tek Sakura Fintek
TBST 1 % Tween 20 Sigma
50 mM Tris Roth
150 mM NaCl Roth
Goat serum
MOWIOL Sigma Aldrich
Rabbit polyclonal TH Milipore
Rabbit anti Tan ap63 1:20000 RUB house made
Mouse anti-NC82 antibody 1:10 DSHB
Goat anti-rabbit antibody 1:400 Molecular Probes
Goat anti-rat 1:400 Molecular Probes
Dako Cytomation Glycergel DakoCytoma-tion
Instrument Company
Leica HM 5030 Cryostat Leica
Leica TCS SP2 confocal Leica
Zeiss LSM 510 Zeiss
2.5 Chemical and Material used for Proteomics Experi-
ment
In this proteomics study, commercially available chemicals were purchased from the fol-
lowing companies: AppliChem, Applied Biosystems, Abcam, BioRad, BMG Labtech,
Dako Cytoma-tion, Dr. Maisch GmbH, DSHB, Emsure, Eppendorf, Expedeon, GFL,
GL Science, Invitrogen, Life Technologies, Leica, Molecular Probes, Merck, Microsoft,
Milipore, Promega, Pierce, Proxeon, Roth, Roche, Sigma-Aldrich, Sigma, Sakura Fintek,
Sigma Life Science, Thermo Scientific, Thermo Fischer, Ultra pure Roth, Waters,Wako,
Zeiss and 3M. However, the detail list of chemicals is written below.
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Table 2.3: Material and chemical used for Protein quantification
Chemical Company
BSA Sigma
SDS ultra pure Roth
Assay DC BioRad
Accessories Company
96-Well Platte ThermoFischer
Fluo32 Software BMG Labtech
BMG Fluostar Galaxy BMG Labtech
Table 2.4: Material and chemical used for Proteomics
Chemical Company
Amoniumbycarbonate Sigma Life Science
Ethanol Emsure
Acetone Roth
DTT Sigma
iodoacetamide Sigma
Lys-C Wako
Acetonitrile Sigma
Trifluoroacetic acid Applied Biosystems
Methanol Sigma
Acetic acid AppliChem
C18-AQ RepoSil-Pur, 3 µm Dr. Maisch GmbH
EMPORE C18 Extraction Disks 3M
Instrument Company
Thermomixer Eppendorf
Speed Vac Eppendorf
Accessories
C-18-Harz Waters
2.5.1 In-solution digest
1 day, 10 days and 30 days old flies head were subjected for this experiment and 100
frozen flies head from each genotype and each time point were homogenized using a
pestle. Samples were lysed with 4% SDS buffer followed by incubating the samples at
950C for 3 min. DNA shearing was performed by subjecting the samples to treatment
with a sonicator (Branson Sonifier 250). Samples were then clarified by centrifugation
at 16000g for 10 min and the supernatent was collected. Protein concentration was
measured by using Bradford Assay Kit (Biored, USA) according to the manufacturers
instructions. A pool of heavy samples was made by mixing identical amount proteins
from 1,10 and 30 days old heavy flies head protein. For each sample, 5 µg proteins
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from mixed Lysine-6 labeled fly head was spiked-in equally with protein samples from
ddc-Gal4 line, transgenic flies head. Acetone precipitation was started by adding four
times the sample volume of cold (-200C ) 100 % acetone (Applichem GmbH, Germany)
and 1 µl of GlycoBlue (Ambion, USA) to the samples. The samples were subjected
to vortex and incubated for 60 min at -200C . After 10 min centrifugation (15000g) of
samples at 400C , supernatent was carefully disposed without being dislodged the protein
pellet. Proteins pellet was washed with 100 µl of 90 % cold (-200C ) acetone followed by
centrifuging (15000g) the samples for 10 min at 400C and supernatant was taken out to
allow the complete evaporation of acetone. Proteins pellet was dissolved by adding 20µl
of 6M urea/ 2M thiourea (Sigma Aldrich, Germany) and by vortexing thoroughly the
samples. Next, we followed In-Solution digests protocol as described previously [143].
Briefly, disulphide bonds of protein mixture were reduced by adding dithiotreitol (100
mM) (DDT, Sigma Aldrich) for 30 min at room temperature. Alkylation of the samples
was carried out by the addition of 550 mm iodoacetamide (Sigma Aldrich) for 20 min in
the dark. The sample mixture was digested with LysC (enzyme:substrate ratio of 1:100)
(Wako) at room temperature for 3 h and later on an overnight incubation with LysC
was done at room temperature. The obtained peptides digestion was stopped by adding
Buffer C (5% acetonitrile in 1% trifluroacetic acid). Stage Tips (Stop and Go Extraction
Tips) preparation was done in two simple steps, first, two small discs of C18 Empore
filter were punched out using an MPI house made puncher and second, ejection of these
two discs into P200 pipette. These stage tips were conditioned by 20 µl methanol and
buffer B (80% ACN, 0.1 % formic acid) followed by equilibrating in 0.1% formic acid.
Peptide mixtures were then subjected to go through the C18 Empore column in order to
bind the peptides with C18 material. Before MS analysis, peptides elusion from Stage
tips was done by applying buffer C (80% ACN, 0.1% formic acid) into 96 well plates.
Elluted Samples were dried in a SpeedVac to 2 µl and 15 µl final volume was made by
adding 13 µl buffer A (0.1% formic acid (FA/H2O)). Finally 4 µl samples were applied
for LC-MS/MS analysis.
2.5.2 In-gel digestion
Flie’s heads were subjected for this experiment and 100 frozen flies head from each
genotype were homogenized using a pestle. Samples were lysed with 4% SDS buffer and
incubated at 950C for 3 min. DNA shearing was performed with a sonicator (Bran-
son Sonifier 250) and samples were then clarified by centrifugation at 16000g for 10
min followed by the supernatent collection. Protein concentration was measured by
using Bradford Assay Kit (Biored, USA). Next, We followed In-gel digestion protocol
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as described previously [144]. Briefly, samples were loaded with 10 µl 4x LDS (Novex,
Germany) loading buffer and 1 µl DDT followed by boiling the samples for 10 min at
950C .Afterwards samples were run on 4-12% SDS/NuPAGE Bis-Tris gels (Invitrogen,
Germany), and were separated on an SDS-PAGE based on their molecular weight fol-
lowed by the staining the proteins in gel.
Table 2.5: SDS-page materials
Chemical Company
DTT Sigma
InstantBlue Expedeon
NuPAGE LDS Sample Buffer (4x) Invitrogen
NuPAGE 4-12% Bis-Tris gels Invitrogen
NuPAGE MOPS SDS Running Buffer (20x) Invitrogen
Instrument Company
Shaker GFL
Thermomixer Eppendorf
We cut each lane into 5 pieces and destaining of gel pieces was done by using 50mM am-
monium bicarbonate and ethanol. Disulfide bonds of protein mixtures were reduced by
addition of fresly prepared 10mM dithiothreitol (DTT) and subjected to vortex for al-
lowing the reaction to proceed at 560C for 45 min. Iodoacetamide (55mM) was added to
the samples to alkylate cysteines residues in the protein samples and vortexed briefly to
continue the reaction in the dark for 30 min at room temperature. These two (reduction
and alkylation of cysteines residues) steps improve the recovery of cystine-containing
peptides from in-gel digests which minimizes the appearance of unknown masses in MS
analysis due to disulfide bond formation and side chain modification. Since Trypsin is
not stable when pure and non-acidic condition, we diluted down to 12 ng/µl from the
stock solution. Therefore, digestion of the proteins in the gel pieces was carried out
with 12 ng/µl Tripsin (Promega) and was kept for overnight digestion at 370C .Peptide
digestion was stopped by acidification with trifluoroacetic acid (TFA) on the next day
and peptides elution were made from the gel pieces with ascending concentrations of
acetonitrile (ACN). The samples were then vacuum evaporated by using SpeedVac con-
centrator plus (Eppendorf) and mixtures were desalted using C18-based Stage Tips [91].
Briefly, Stage tip was prepared by ejecting two small discs of C18 Empore filter into P200
pipette and were conditioned by 20 µl methanol and buffer B (80 % ACN, 0.1 % formic
acid) followed by equilibrating in 0.1 % formic acid. Peptide mixtures were then forced
to bind with C18 material. Before MS analysis, peptides elusion was done by applying
buffer C (80% ACN, 0.1% formic acid) and samples were concentrated to 2 µl . A final
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volume of 10 µl was made by adding 8 µl buffer A (0.1% formic acid (FA/H2O)) and
4 µl samples were applied for LC-MS/MS analysis.
2.6 Immunoprecipitation
The ddc-Gal4 line was used to overexpress hLRRK2 and hLRRK2 (R1441C) in DA neu-
rons of Drosophila. Thirty days old flies were choosen and 200 frozen flies head from
each genotype were homogenized using a pestle. Samples were lysed by using 1X RIPA
buffer at 40C . DNA shearing of the samples was performed with a sonicator (Branson
Sonifier 250). Samples were subjected to centrifugation at 16000g for 10 min and the
supernatent was collected. Protein concentration was measured by using Bradford As-
say Kit (Biored, USA) and 1 mg protein was taken from each genotype. In total 30 µl
anti-FLAG (Sigma) bead was added per 1 mg sample and incubated for 3 hours with
rotation at 40 C. Samples were centrifuged (16000g) for 10 min at 40 C and supernatants
was taken out. We washed the beads three times with 1X RIPA buffer with 1 min
centrifugation at 1000 g between each washing step. The beads were collected and the
samples were loaded with 10 µl 4x LDS (Novex, Germany) loading buffer and 1 µl DDT
followed by boiling the samples for 10 min at 950C . Afterwards samples were run on
4 to 12 % SDS/NuPAGE Bis-Tris gels (Invitrogen, Germany) and in-gel digestion was
performed for MS analysis in order to quantify the interaction partner.
Table 2.6: Material and chemical used for immuneprecipitation
Chemical Specification Company
RIPA-Buffer 50mM Tris-HCl pH 7.5 Ultra pure Roth
150 mM NaCl Roth
1% NP-40 Sigma
1 mM EDTA Roth
0,1% Natriumdeoxycholate Sigma
PhosStop Roche
Protease Complete Roche
SDS ultra pure Roth
ANTI-FLAGM2 Affinity Gel Sigma
SeeBluePlus2Standard Invitrogen
Trypsin Promega
Instrument Company
Centrifuge Eppendorf
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2.7 Western blot analysis
Adult fly heads were homogenized in 4 % SDS buffer and proteins were extracted fol-
lowed by incubating the samples at 950C for 3 min. DNA shearing was performed
by a sonicator (Branson Sonifier 250). Samples were then subjected to centrifugation
at 16000g for 10 min and the supernatent was collected. Protein concentration was
measured by using Bradford Assay Kit (Biorad, USA) to ensure equal protein loading.
Thirty µg of lysate from control and transgenic flies head were mixed with 6 µl volumes
of 4x NuPAGE LDS sample buffer, 2µl 40 mM DTT and heated at 950C for 5 min.
Proteins were separated based on their molecular weight in SDS/NuPAGE Bis-Tris gels
and transferred onto nitrocellulose membranes (Milipore). The membranes were blocked
in TBST (pH 7.4, 10mM Tris-HCl/150mMNaCl/0.1 % Tween 20) containing 5% nonfat
milk at room temperature and probed overnight at 4 0C with the respective primary
antibody. Protein detection was done by using enhanced chemiluminescence reagents
(Pierce) and visualized by an Image (VersaDoc).
Table 2.7: Instrument and chemical used for Western Blot
Chemical Specification Company
Transferpuffer 10 % Methanol Sigma Aldrich
25 mM Tris Ultra pure Roth
192 mM Glycin Roth
TBS-T 1 % Tween 20 Sigma
50 mM Tris Roth
150 mM NaCl Roth
BSA 5% Sigma
Milk powder 5% Roth
AGO2 Antibody 1:1000 Abcam
Tan Antibody 1:2500 RUB house made
Goat anti-rabbit antibody 1:1000 Pierce
Instrument Company
VersaDoc BioRad
Accessories
Gel Life Technologies
Developing solution Thermo Scientific
Whatman Paper Roth
Nitro cellulose membrane Roth
2.8 Immunocytochemistry
The proboscis was removed from 4 weeks old flies in ice-cold 4% paraformaldehyde in 0.1
M phostphate buffer pH 7.4. Tissues were allowed to fix for 3 h at 40C . The fixative was
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replaced by 25 % sucrose in Ringers solution and flies were incubated overnight at 4 0C .
Heads were embedded in Tissue-Tek (Sakura Fintek, Zoeterwoude, The Netherlands)
and frozen in liquid nitrogen. Sections were made using a Leica HM 5030 Cryostat.
Probes were washed twice for 10 minutes with TBST and blocked with 1 % normal goat
serum (NGS) in TBST for 30 minutes (all at RT). First antibodies were applied at 4
0C over night at the following dilution: Rabbit anti Tan ap63 1:20.000 and mouse anti-
NC82 1:10 (DSHB, Iowa, United States). Slides were incubated at RT for 30 minutes,
washed twice 10 minutes with TBST and incubated with 2nd antibodies 1:400 in TBST
1 % NGS (Alexa488 conjugated goat anti rabbit, Alexa594 conjugated goat anti rat,
Molecular Probes) overnight at 4 0C . After washing twice 10 minutes at RT using
TBST slices were mounted in DakoCytomation Glycergel (DakoCytoma-tion, Hamburg,
Germany) and probes were imaged using a a Leica TCS SP2 confocal microscope. In
order to obtain comparable results, all procedure was done simultaneously using probes
and control genotypes.
2.9 Sample preparation for phosphoproteome
Thirty days old control and transgenic flies were selected for phosphoproteomics ex-
periment Flies heads were lysed with 4% SDS buffer and proteins were extracted by
sonication, centrifugation at 16000g for 10 min followed by the supernatent collection.
Bradford Assay Kit (Biorad, USA) was used to estimate the protein concentration. One
mg proteins from each genotype were taken and spiked-in equally with proteins from
SILAC fly’s head. Acetone precipitation of the samples was executed by adding four
times the sample volume of cold (-200C ) 100 % actone (Applichem GmbH, Germany)
and 1 µl of GlycoBlue (Ambion, USA). The samples were then vortex and incubated for
60 min at -200C . After centrifugation with 15000g at 400C , supernatent was discarded.
Proteins pellet was washed with 90 % cold (-200C ) acetone followed by centrifuging
(15000g) the samples for 10 min at 400C and supernatant was taken out to allow the
complete evaporation of acetone. Pellet was dissolved by adding 300 µl of 6M urea/ 2M
thiourea (Sigma Aldrich, Germany). Disulphide bonds of protein mixture were reduced
by adding 1 % DDT (100 mM) of total sample volume for 30 min at room temperature.
Alkylation of the samples was carried out by the addition of 10 % 550 mM iodoac-
etamide of sample volume (Sigma Aldrich) for 20 min in the dark. The Proteins were
digested with LysC (enzyme:substrate ratio of 1:100) (Wako) at room temperature for
3 h followed by an overnight incubation with LysC addition at room temperature. The
digested peptide mixture was acidified (pH=2.67) by adding 0.5 % trifluoroacitic acid
(TFA) of total sample volume. Strong Cation Exchange (SCX) method was employed
to separate the phosphopeptides from non-phosphorylated peptides. Peptides samples
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were loaded on ResourceS 1ml SCX column (ta Purifier, Ge Healthcare). A binary
buffer system, consists of solvent A (7mM KH2PO4, 30 % ACN (pH=2.65) and solvent
B (7mM KH2PO4, 350 mM KCI, 30 % ACN (pH=2.65), was used to apply a gradient
run with increasing salt concentration.
Table 2.8: Material and chemical used for Phosphoroteomics
Chemical Specification Company
Amoniumbycarbonate Sigma Life Science
Ethanol Emsure
DTT Sigma
iodoacetamide Sigma
Lys-C Wako
Acetonitrile Sigma
Trifluoroacetic acid Applied Biosystems
Methanol Sigma
Acetic acid AppliChem
AA buffer 7mM KH2PO4 Sigma
30% ACN pH 2.65 Roth
AB buffer 7mM KH2PO4 Sigma
350mM KCL, Sigma
30% ACN, pH 2.65 Roth
AC buffer 50 mM K2HPO4. 3H20 Sigma
500mM NaCl, pH 7.5 Applichem
Binding Buffer 80% ACN
6% TFA Applied Biosystems
Wash Buffer 80% ACN
3% TFA Applied Biosystems
Elution Buffer 60% NH3, pH 11.6
40% ACN
TitansphereTiO2 beads GL Science
C8, 12 ?m Sigma Aldrich
Instrument Company
Thermomixer Eppendorf
Speed Vac Eppendorf
taPurifier GE heathcare
The SCX fractions containing phosphopeptides were separated based on their charge and
were collected in Eppendorf tubes. The FT and fractions were concentrated for several
hours (∼ 4 hours) by SpeedVac to a final volume of 100-250 µl so that they can be
processed using eppendorf tubes during extraction. In total, 6 fractions were collected,
including flow-troughs from each sample after pooling and were adjusted for binding
conditions of Titan sphere (TiO2 ) bead based phosphopeptides extraction. Appropriate
amount of TiO2 beads (SLSC) was adjusted based on phosphopeptides concentration
and beads were washed consecutively with 60 % NH3 (pH 11.2) / 40% ACN, 70 % ACN
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and washing buffer (80% ACN/3% TFA) followed by resuspended in binding buffer (80%
ACN / 6% TFA). Extraction steps were performed by adding the right amount of beads
to the samples and incubate on a rotating wheel for few times (three times for flow-
troughs and two times for fractions) for 25 min followed by centrifuged at 2000g for
2 min for Eppendorf tubes or 5 min for falcon tubes. Beads were pooled and washed
two times each with binding buffer (80% ACN/6% TFA), and washing buffer (80%
ACN/3% TFA) to remove the remaining non-adsorbed material. These beads were
loaded on C8 material tips and phosphopeptides elution was done with elution buffer
(40 % Amonia/Acetonitrile (pH=11.6)). The eluted phosphopeptides were concentrated
to 2 µl followed by reconstituted with 8 µl 0.1 % formic acid and finally, 4 µl samples
were applied for MS analysis.
2.10 Liquid chromatography configuration
All nano scale liquid chromatographic seperation was done by using an online Easy nLC
nanoflow HPLC system (Proxeon Biosystems, Odense, Denmark now Thermo Fisher Sci-
entific). Briefly, reversed phase separation of peptides was done by using an Easy nLC
nanoflow HPLC system with a column with 50 cm length and 75 µm inner diameters,
packed in-house with RepoSil-Pur C18-AQ 1.9 µm resin (Dr. Maisch, Ammerbuch-
Entringen, Germany). Peptides elusion was performed in fraction optimized linear gra-
dient from 7 % to 35 % B over duration of 220 min followed by 95% buffer B for 10
min and then re- equilibration to 5% buffer B for 10 min. The column temperature was
controlled by using a custom-made column oven at 400C .
2.11 Mass spectrometry configuration
The precursor ion accurate masses and associated fragment ion spectra of the lysine/tryp-
tic peptides were measured by Q Exactive (Thermo Scientific, Bremen, Germany) as
described previously [131]. We operated the mass spectrometer in positive ion mode
and employed a data-dependent automatic switch between MS and MS/MS acquisition
modes. The capillary temperature was 2750C and the S-lens RF level was set to 64.
MS1 spectra were acquired using a resolution of 70,000 (at 200 m/z), an Automatic Gain
Control (AGC) target of 3e6, and a maximum injection time of 20 ms in a scan range
of 300-1750 Th. In a data dependent mode, the 10 most intense peaks were selected
for isolation and fragmentation in the HCD cell using a normalized collision energy
of 25. Dynamic exclusion was enabled and set to 25 s. The MS/MS scan properties
were: 17.500 resolution at 200 m/z, an isolation window of 2.1 Th an AGC target of
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5e5 and a maximum injection time of 60 ms. The gradient and settings for MS/MS
Scans properties were different for phosphoproteome experiments: Gradient time was
150 min and the MS/MS scan resolution was 35.000 (200 m/z), max. injection time was
120 ms aiming for an AGC target of 5e5, and an isolation window of 1.8 Th was used.
In−vitro kinase assay was measured with similar settings but a gradient time of 60 min
was applied. Immunoprecipitation experiments were performed with a LTQ-Orbitrap
Velos mass spectrometer (Thermo Fisher).
Table 2.9: Instrument and chemical used for Mass-spectrometry
Chemical Company
Acetonitrile Sigma-Aldrich
Acetic acid Appli Chem
LTQ Velos ion ESI Positive Calibration Solution Pierce
Q-Exactive ion ESI Positive Calibration Solution Pierce
Methanol Sigma-Aldrich
Formic acid Merck
Instrument Company
Q-Exactive Thermo Scientific
LTQ Orbitrap Velos Thermo Scientific
UHPLC Proxeon
Electrospray ion source Proxeon
Column oven MPI House made
2.12 Proteomic Data Processing
2.12.1 Data Analysis
The MS raw datas were analyzed by MaxQuant software (developmental version 1.4.7.2)
[104] to identify and quantify proteins. MaxQuant software analyzes the data by three
main components, namely, feature detection and peptide quantitation (Quant.exe), Iden-
tification and validation (identify.exe) and Visualization (Viewer.exe). It processes an
entire set of algorithms in detecting peaks, isotopes and quantify relative peak intensities
of SILAC partners, as well as in performing statistics to large scale proteomic datasets.
An eight folds improvement in mass accuracy has been achieved through its smart strat-
egy where it uses different charged states of the same peptide for non-linear recalibra-
tion and those well identified peptides for global mass re-calibration. These identified
peptides are rescued through this approach instead of falling out of the required mass
accuracy window and therefore, it enhances the global identification statistics. Since
SILAC approach is different from the conventional method, Maxquant allows SILAC
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partners to be classified into groups which treats heavy amino acid labeling as a fixed
modification and hence SILAC partners detection in MaxQuant is performed before the
identification. This policy in Maxquant significantly shortens the time for database
search, since too many variable modifications often make it too challenging to derive
the data analysis in time. Moreover, the new strategy also restricts the possibility of
mismatch.
Table 2.10: Used software
Software Company
MaxQuant MPI Martinsried
MaxQuant Viewer MPI Martinsried
Perseus MPI Martinsried
Excel Microsoft
Andromeda Config MPI Martinsried
Illustrator Adobe
Photoshop Adobe
MS File Reader Thermo Scientific
Xcalibur ThermoFisher
R University of Auckland
2.12.2 Identification
The quant.exe processes the raw MS data and the pick list was searched using An-
dromeda search engine [145] against the database of D.melanogaster (flybase, release
5.13, Indiana University, IN, USA) with common contaminants. However, Human
Parkinson’s genes sequences were added in the Drosophila fasta files in order to identify
those transgenes in our analysis. Carbamidomethylation of cysteine was taken as fixed
modification and SILAC partners were classified with MaxQuant based on their labeling
such as heavy, medium and light. Therefore, these were also set as fixed modification
within each group. Oxidation of methionine and acetylation of the protein N-terminus
were selected as variable modifications. However, Phospho (STY) was also included as
variable modification for phosphoproteomics analysis. As a protease, LysC and trypsin
was chosen with a maximum of 2 missed cleavages. Mass tolerances for selected frag-
ment ions was set to 0.5 Da and initial mass deviation of precursor ion was kept 10
ppm. The identified peptides and their corresponding proteins were further processed
with Identify.exe. The probability of having a random peptide match for each spectrum
was estimated by the Posterior error probability (PEP) calculation. False discovery rate
(FDR) represents the false identified hits percentage in the entire data set. However,
we employed the following standard operating procedures in our study to achieve highly
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reliable identifications. For Proteome dataset, peptide PEP <0.1, peptide FDR <0.1,
protein FDR <0.1. A peptide with minimum six amino acids and at least two peptides
per protein group were taken where one peptides should be unique to that protein. Al-
though a single peptide can be utilized for the protein quantification , we required a
minimum of two peptides for a protein to be considered for quantification in the present
study. For Phosphoproteome dataset, peptide PEP <0.1, peptide FDR <0.1, protein
FDR <0.1, peptide length >6 . The whole phosphorylation analysis was performed at
the peptide level.
2.12.3 Quantification
Protein quantification in MaxQuant software was done by calculating peptide ratios
based on the intensities of all 2D centroids from each of the SILAC forms and through
linear line fitting of these intensities, a slope was given which denotes a ratio. SILAC
labeling (element enrichment in 13C) were also included into account during this calcu-
lation. In addition, the median value was chosen to represent the peptide ratio if the
peptide was quantified several times. However, protein ratios were the outcome from
the median of all SILAC pair peptide ratios that belong to that protein and this cer-
tainly minimized the effect of outliers. A suitable threshold of 1.5 fold changes were
considered a significant biological regulation. We reasoned that peptides from the same
protein can result a decent standard deviation among the measured peptide ratios due to
their individual drastic difference. Therefore, if a protein exhibits 1.5-fold change from
multiple peptides in both duplicate experiments, it will be considered as a differentially
expressed protein. Furthermore, proteins that exhibited 1.5-fold changes and identified
in only one of the experiments were discarded to reduce suspicious protein candidates.
Upregulated and downregulated expressions were presented with positive and negative
ratio values, respectively in all the projects in this thesis.
2.13 Quantify the localization of phosphate group
Localization probability denotes the probability to detect specific phosphorylation site
localization within different potential phosphorylated site locations when multiple ser-
ines, thereonines, or tyrosines are present in the sequence. MaxQuant calculated the
localization probability score for each possible phosphorylation site by matching the ob-
served b and y ions with the theoretical b and y ions [146] and displayed in MaxQuant
output tables. Two simple processing steps were followed for the phosphoproteome anal-
ysis in order to assign a phosphorylation site accurately: first ignored the entries with
post-translational modifications (PTM) scores that were lower than the maximum score
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minus five and second, counted those modification where localization of PTM probabil-
ities were at least 0.75.
2.14 Bioinformatic analysis
Most of the statistical analysis and graphical visualization were done by using the open
PERSEUS environment (Part of MaxQuant). Significant differently expressed proteins
were identified by using a two-sided t-test and a cutoff, if not stated differently, of log2
fold change >0.58 and p value <0.05 was used. However, R framework was also used
for several calculations and plots. The category assignment and GO terms enrichment
were done in the Perseus environment. The comparison between Drosophila and hu-
man databases were carried out as described previously [147]. Briefly, the software tool
(BLAST 2.2.28+) was used for sequence comparison (BLAST search). All Uniprot iden-
tifiers of the Drosophila database with 18012 protein entries were searched against the
human reference proteome. The results were extracted by the Drosophila ID importing
the best blast hit. The Uniprot IDs of proteins was used to show the protein interaction
network through STRING [148] and enrichment of functional GO [149] categories was
performed using Gorilla tool [150] and PantherDB [151].
2.15 In vitro phosphorylation assay
In total, 0.31 µg/µl of purified synaptojanin (Origene) was incubated with 1 nM purified
LRRK2 (Invitrogen) or LRRK2 (R1441C) or LRRK2 (D1994A) in 5 µl 10x kinase buffer
(Cell Signalling Technology), 1 µl [γ- 32P] ATP (1 µCi) with a final vollume of 15 µl
without incubation and 60 minute at 300C . In addition, increasing concentration (0.075,
0.3, 0.5 and 1 µm) of LRRK2 inhibitor LRRK2-in-1 was added in the mixtures and
incubated for 60 minute at 300C . The reaction mixtures were terminated by adding 5
µl of 4x SDS sample buffer (Invitrogen) followed by denaturing the samples at 1000C for
10 minutes. As a control, we used either Synaptojanin or LRRK2 kinase alone with rest
of the ingredients. Each sample was loaded into 10 well 4-12 % Bis-tris polyacrylamide
gel (Invitrogen) and run at 160 v for 2 hour. The gels were made dry and were subjected
to autoradiography.
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Table 2.11: Kinase assay
Chemical Company
LRRK2 Invitrogen
LRRK2 (R1441C) Invitrogen
LRRK2 (D1994A) Invitrogen
LRRK2-In-1 Millipore
Synaptojanin Origene
MBP Sigma-Aldrich
Kinase buffer Cell Signaling Technology
32 ATP PerkinElmer, Inc
4 x LDS sample buffer Invitrogen
Protein standards Invitrogen
MOPS running buffer Invitrogen
Bis-tris acrylamide gel Invitrogen
Geiger counter Mini Instriments
Heat blocks Eppendorf
Phosphor screen GE Heathcare
Phosphor imager GE Heathcare
Exposure cassette GE Heathcare
Centrifuge Eppecdorf
Perspex shielding
1.5 ml tubes VWR international
Chapter 3
Results
3.1 Overexpression of Human LRRK2 (R1441C) induces
Parkinsonism phenotypes in Drosophila
Mutations in LRRK2 lead to late onset autosomal dominant PD and previously, it was
reported that the overexpression of hLRRK2 (G2019S) in the fly’s brain caused PD
phenotypes which includes climbing disability, shorter lifespan, retinal degeneration and
the DA degeneration [72]. In this study, we also generated a novel hLRRK2 (R1441C)
transgenic PD model flies by using Gal4/UAS system and overexpression of hLRRK2
(R1441C) induced severe PD phenotypes in flies which will be described in the following
sections.
3.1.1 Transgenic human LRRK2 (R1441C) Drosophila
In collaboration with Prof. Dr. Bernhard Hovemann, molecular biochemistry, we gen-
erated human LRRK2 and human (R1441C) transgenic Drosophila as a PD model by
using UAS/Gal4 system that ectopically express the hLRRK2 genes in Drosophila DA
neurons and full brains. The successful overexpression of FLAG-tagged hLRRK2 in
Drosophila brain was confirmed by immunoblotting, see fig. 3.1 B. A strong band at
265 kDa was observed in both hLRRK2 and hLRRK2 (R1441C) flies, however this band
was not found in ddc-Gal4 flies.
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Figure 3.1: A)Schematic representation of the hLRRK2 domain structure. B) Ex-
pression of hLRRK2 and hLRRK2 (R1441C) in the Drosophila brain. Western blots
from the heads of flies show ddc-driven hLRRK2 and hLRRK2 (R1441C) expression in
the Drosophila brain.
3.1.2 Overexpression of hLRRK2 (R1441C) in the retina results in
degeneration of photoreceptors
The Gal4/UAS expression system has been widely used in fly to ectopically overexpress
transgenes in a tissue specific manner. To test whether the hLRRK2 and its substituted
version have an impact on neuronal cell homeostasis in Drosophila, we first established
a transgenic strain which overexpress hLRRK2 under the control of the glass multiple
reporter (GMR) [152]. Degeneration of photoreceptor cells was used to assay neuronal
degeneration previously [72], therefore we used the degeneration of photoreceptor cells to
prove whether hLRRK2 and hLRRK2 (R1441C) causes neurodegeneration when overex-
pressed in flies. The Drosophila compound eyes are made of v 800 repeat units, called
ommatidia, that includes seven photoreceptor cells (R1-R8) in given plane of section.
Each photoreceptor cell has a rhabdomere, a microvillar structure, used for photorecep-
tion which resembles rod and cone outer segment from invertebrate. To examine the
kinetics of retinal degeneration, we used an optical neutralization technique over seven
weeks age at standard temperature and the data was generated by the examination of
at least 90 ommatidia from six flies per genotype. We detected mild but progressive
degeneration in the eyes of GMR control flies from fourth week until the end of the
study at seventh week, see fig. 3.2 A. Figure 3.2 B shows that the overexpression of
hLRRK2 (R1441C) caused a more severe and faster photoreceptor degeneration com-
pared to hLRRK2 and control flies (p-value< 0.05), respectively. This is consistent with
previous findings that showed hLRRK2 causes retina degeneration in Drosophila [72].
Therefore, these results represent the toxic role of hLRRK2 (R1441C) overexpression in
adult fly’s eyes.
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Figure 3.2: A) hLRRK2 (R1441C) induces retinal degeneration in Drosophila eye
after 4 weeks. Representative images from the optical microscope for each indicated
genotype were examined at their 4 weeks. B) The time course of photoreceptor degen-
eration determination by optical neutralization technique. Each data point was based
on examination of > 90 ommatidia from at least 6 flies. One way ANOVA, Bonfer-
onni’s post-hoc test. # p < 0.05 GMR-Gal4 vs. hLRRK2, + p < 0.05, ++ p <
0.01, +++ p < 0.005 GMR-Gal4 vs. hLRRK2 (R1441C), § p < 0.05, §§§ p < 0.01
hLRRK2 vs hLRRK2 (R1441C).
3.1.3 Early mortality and locomotion disability in ddc-Gal4 driven hLRRK2
and hLRRK2 (R1441C) strains
Since DA degeneration is tightly associated with movement disorder [153], next we ex-
plored whether the LRRK2 overexpression in DA neurons would induce an obvious
locomotor phenotype in flies. We overexpressed hLRRK2 and hLRRK2 (R1441C) in
DA neurons by combining the UAS-LRRK2 and UAS-LRRK2 (R1441C) transgenic
strains with the dopadecarboxylase (ddc)-GAL4 driver [71]. Both hLRRK2 forms were
tagged with a Flag at the n-terminus and fig. 3.1 B showed western blot analysis of both
hLRRK2 proteins expression in brain tissue. In order to further test the phenotype of
hLRRK2 expressing flies, we measured survival curves obtained from control (ddc-Gal4
and UAS-LRRK2), hLRRK2, and hLRRK2 (R1441C) flies. Our data indicated that
hLRRK2 flies have a significant shorter life time compared to control flies. On average,
we observed a negative effect (-17.5%) on the mean life span. Interestingly, significantly
larger changes (-34%) to the median life span were observed for hLRRK2 (R1441C) flies
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Figure 3.3: A) ddc-hLRRK2 (R1441C) causes short life span. Survival curves of
flies (n=50) expressing either hLRRK2 or hLRRK2 (R1441C) under ddc-Gal4 driver.
B) hLRRK2 (R1441C) expression by ddc-Gal4 causes locomotion disability. 50 flies
were subjected to climbing essay. One way ANOVA, Bonferonni’s post-hoc test. *p <
0.05 UAS-LRRK2 vs ddc-Gal4, # p < 0.05, # # p < 0.01 ddc-Gal4 vs hLRRK2
(R1441C)). § p < 0.05, §§ § p < 0.01 hLRRK2 vs hLRRK2 (R1441C).
( fig. 3.3 A). Thus, our data indicate that a specific hLRRK2 expression in DA neurons
reduces the average life span in adult flies significantly and in addition the hLRRK2
(R1441C) mutation apears to be more toxic to DA neurons compared to the regular
hLRRK2 overexpression.
Since PD is a movement disorder, we next investigated whether the overexpression of
hLRRK2 (R1441C) in DA neurons can cause Parkinsonism phenotype similar to other
PD model. Therefore, we performed a climbing assay (negative geotaxis test). Initially
flies from all genotypes rapidly climbed to the top of the vial when they were tapped. As
they get older, hLRRK2 (R1441C) and hLRRK2 flies started to show climbing disability
compared to their aged matched controls ( fig. 3.3 B). First, we tested flies with an age
of 2 weeks and observed no obvious changes between control and hLRRK2 overexpress-
ing flies (n=60). However, during aging, we found a progressive loss of climbing ability
in hLRRK2 and hLRRK2 (R1441C) flies. Notably, Drosophila expressing the LRRK2
(R1441C) showed a more severe effect, suggesting again enhanced biological toxicity of
hLRRK2 (R1441C) in DA neurons.
3.1.4 hLRRK2 (R1441C) causes reduced tyrosine hydroxylase enzyme
in a subpopulation of DA neurons
Degeneration of DA neurons is a pathological hallmark of PD and therefore, we inves-
tigated the consequences of DA neurons due to hLRRK2 (R1441C) overexpression in
flies.
There are few neuronal DA clusters represents the adult brain hemisphere and these
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Figure 3.4: Overexpressed hLRRK2 (R1441C) degenerates DA neurons in
Drosophila. A) Different DA clusters in flies brain and a representative image of TH
staining in whole-mount 6 weeks old flies immunostained with primary mouse anti-TH
antibody and secondary anti-mouse Alexa-Flour 568 antibody. B) Quantification of
TH-positive neurons in control hLLRK2, hLRRK2 (R1441C) and ddc-gal4 6 weeks old
flies. Dorsolateral posterior protocerebral (PPL1) and dorsomedial posterior protocere-
bral (PPM1/2) showed statistically significant differences between ddc-Gal4, control
hLRRK2 and hLRRK2 (R1441C) that were indicated: ** p< 0.01, ***p< 0.005 one
way ANOVA, Bonferonni post-hoc test. C) Degeneration of DA neurons in different
DA clusters. Posterior prorocerebral (PPL1 and PPL2a/b) cluster and protocerebral
anterior medial (PAM) showed complete DA neuronal degeneration in mutant flies.
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Figure 3.5: A) elav-hLRRK2 (R1441C) causes short life span. Survival curves of
flies (n=50) expressing either hLRRK2 or hLRRK2 (R1441C) under elav-Gal4 driver.
B) hLRRK2 (R1441C) expression by elav-Gal4 causes locomotion disability. 50 flies
were subjected to climbing essay. One way ANOVA, Bonferonni’s post-hoc test. *
p< 0.05 UAS-LRRK2 vs elav-Gal4, # p< 0.05,## p< 0.01 elav-Gal4 vs hLRRK2
(R1441C)). § p< 0.05, §§§ p< 0.01 hLRRK2 vs hLRRK2 (R1441C).
neurons express tyrosine hydroxylase (TH) enzyme, an essential part for biosynthesis of
dopamine. We analyzed posterior paired DA clusters in 6 weeks old Drosophila brain:
dorsolateral posterior protocerebral (PPL1), lateral posterior protocerebral (PPL2a/b),
two dorsomedial posterior protocerebral custers (PPM1/2 and PPM3), protocerebral
anterior lateral (PAL) and protocerebral anterior medial (PAM)[154], see fig. 3.4 A. TH
positive neurons in the DA clusters did not change significantly in number or morphol-
ogy during aging in control Canton S and ddc-GAL4 flies. However, all 6 weeks old WT
and mutant LRRK2 flies showed some significant or a trend of neuronal loss in PPM1/2
(P< 0.01) and (P< 0.001) compare with ddc-Gal4 line respectively. In addition, PPL1
clusters also indicated significant (P< 0.01) DA degeneration in LRRK2 flies compare
with ddc-Gal4 flies. Remarkably, we found complete degeneration of DA neurons in
PPL1, PAL and in PPLa/b clusters from mutant flies compare with control flies and
ddc-Gal4 flies as shown in fig. 3.4 B. The effect in PAM and PPM3 did not reach the
significant statistical significance [74] and thus, the overall prominent effect was observed
in PPM1/2, PAL, PPL2a/b clusters in hLRRK2 (R1441C) flies when compared against
control flies ( fig. 3.4 C) .
3.1.5 Ectopic overexpression of hLRRK2 (R1441C) in all neurons in-
duces late-onset mortality and late-onset locomotion impairment
To further examine the effect of hLRRK2 (R1441C) over all neurons in Drosophila, we
overexpressed hLRRK2 (R1441C) under the control of the panneuronal driver elav-Gal4,
the embryonic lethal abnormal visual system gene (elav)-Gal4.
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Figure 3.6: A) ddc-αS flies cause short life span. Survival curves of flies (n=50)
expressing either αS or A30P-αS, A53T-αS under ddc-Gal4 driver. B) αS expression
by ddc-Gal4 causes locomotion disability. 50 flies were subjected to climbing essay. One
way ANOVA, Bonferonni’s post-hoc test. * p< 0.05 α S vs ddc-Gal4,# p< 0.05,
# # p< 0.01 αS vs A30P-αS, § p< 0.05, §§§ p< 0.01 αS vs A53T-αS.
The panneuronal expression of both hLRRK2 and hLRRK2 (R1441C) under the con-
trol of elav-Gal4 driver lead to shortened lifetime and significant motor impairment
in hLRRK2 transgenic flies compared with control flies ( fig. 3.5). These elav driven
transgenic flies showed significant motor impairment after 6 weeks as shown in fig. 3.5
B and the climbing ability of hLRRK2 (R1441C) mutant flies showed rapid declination
relative to hLRRK2 flies. Therefore, unlike our previous results these phenotypic vari-
ations in elav driven transgenic flies also represent the toxic role of both hLRRK2 and
hLRRK2 (R1441C) over all neurons which might lead to common PD phenotypes in flies.
3.2 Alpha sy-nuclein (αS) A30P and A53T Drosophila model
of PD
In order to screen the LRRK2 specific toxicity for PD phenotypes, we also included the
αS Drosophila model of PD in our study. Hence, we overexpressed A30P-αS, A53T-αS
and αS in flies under the control of the ddc-Gal4 driver and reexamined the early mor-
tality and climbing disability as discussed previously [71]. The surviving essay demon-
strated that A30P-αS overexpression lead to severe PD phenotype, such as shortened
lifetime compared to αS transgenic and control flies (fig. 3.6 A).
Interestingly, αS flies and A53T-αS flies did not show any significant difference in lifetime
as shown in fig. 3.6 A. Although both αS or mutant αS expressing flies exhibited normal
locomotor activity at 1 week after eclosion (fig. 3.6 B), A30P-αS mutant flies showed
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rapid declination of climbing ability at 3 weeks compared to both A53T-αS and αS
flies. Nonetheless, significant locomotor impairment has been also observed for A53T-
αS expressing flies relative to αS flies. Therefore, along with previous studies [71],
our results also signifies αS toxicity in DA neurons that might cause severe locomotor
impairment and shortened lifetime in flies.
3.3 Quantitative proteome analysis of transgenic flies with
stable isotope labeling in living flies
Since we have analyzed the morphological changes and locomotor behavior of our trans-
genic LRRK2 and αS fly models, we next used an unbiased quantitative proteomics
approach to analyze global proteome changes. For accurate protein quantification, we
used the in-vivo stable isotope labeling of amino acids in cell culture (SILAC) method
which is based on the metabolic incorporation of labeled amino acids into living organ-
isms. The SILAC approach has been initially developed for cell culture systems and
recently the method was extended to label also living flies [100]. In order to introduce
the labeled amino acid into flies, we used the natural food source for flies the baker’s
yeast. After labeling the yeast with the stable isotope lysine-6 (13C6 Lysine) the flies
were labeled with this SILAC amino acid by a simple feeding procedure with the labeled
yeast. Fully labeled flies were obtained after one generation and we used the proteins
derived from those SILAC flies as an internal spike-in standard to perform accurate and
robust protein quantification.
3.3.1 Generation of SILAC fly and their labeling efficiency
First the auxotrophic yeast strain S. cerevisiae (S2886 TWY 7) was cultivated in the
presence of stable isotope-labeled 13C6 lysine (from now on Lys6). After 5 days, the
labeling efficiency was tested by in-solution digestion of extracted yeast proteins and
LC-MS/MS analysis. We observed virtually no non-labeled peptides after the MS anal-
ysis and calculated an average labeling efficiency of >97%. Next, non-labeled wild type
flies (strain W 1118) were fed with Lys6 labeled yeast until the F1 generation. Although
both arginine and lysine can be used for SILAC labeling, we used only Lys6 to avoid
arginine to proline conversion [155]. The labeling efficiency of adult flies from the F1
generation was again tested by MS measurements and on average the incorporation rate
was above 97% (fig. 3.7 A). A representative MS spectrum of a fully labeled peptide is
shown in fig. 3.7 B. Of note, the corresponding light isotope of this peptide has a much
lower intensity compared to the 6 Da Lys6 containing peptide (heavy peak). Thus, our
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Figure 3.7: A) Approximately 82 % of total proteins are 100 % labeled and few
proteins are 90-95 % labeled. B) Representative mass spectrum for peptide sequence
(HGVAAITTTK) from heavy adult fly in the F1 generation. The mass difference
between heavy peptide and light peptide is 6 Da due to one heavy lysine.
labeling tests indicate a complete labeling of the flies and we will use extracted proteins
from SILAC labeled flies as a spike-in standard for all subsequent quantitative SILAC-
based experiments.
3.3.2 Metabolic labeling does not change the proteome expression of
D.melanogaster
Next, we examined whether metabolic labeling with lys 6 has any influence on the protein
expression compared to non-labeled control flies. To do so, proteins from Lys6 labeled
fly’s head were extracted and after Bradford test, equal amounts of the non-labeled
and labeled sample were subjected to in-solution digest followed by MS analysis with
a 150 min gradient. The RAW data were calculated with the software tool MaxQuant
(1.3.5.0) and Perseus [156]. In total, we quantified 1737 proteins between both condi-
tions and after log transformation, the ratio differences were plotted against the ratio
frequency (fig. 3.8 A). Notably, the spread of calculated ratios can be used to assess
the proteomics difference between labeled (heavy) control flies and non-labeled (light)
control flies. Here Log2 fold changes ranged from -2 to 2 and more than 90 % of the
protein ratios are between a log ratio of 0 and 0.25 reflecting a very similar expression
profile between both populations. Since, we will use the SILAC fly as a spike-in sample,
we also calculated ratio of the ratio of two independent experiments (between control
flies) and observed most of the protein ratios (95%) are also distributed between -0.25
and 0.25 (Fig. 3.8B). This finding indicates that the both a direct comparison and the
spike-in approach can be used to accurately quantify proteins from isolated fly brains.
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Figure 3.8: A) Proteins ratio distribution between Lys-6 labeled flies and unlabeled
flies, where the majority of proteome ratios are close to 1 (Log2 0 =1). Moreover, 97 %
proteins ratio shows less than 1.5 fold change (Log2 SILAC ratio between 0.5 to -0.5)
in expression level for two biological replicate. B)The spike-in approach shows the ratio
distribution for two independent experiments (control flies 1 / control flies 2).
3.4 SILAC protein quantification in flies overexpressing
hLRRK2 and hLRRK2 (R1441C)
Similar to a previous report from Liu and Co-workers, our morphometric analysis clearly
showed that hLRRK2 and hLRRK2 (R1441C) overexpression in Drosophila severely
compromises DA neurons and causes a Parkinsonism phenotype [72]. To directly study
how hLRRK2 affects DA neurons on the protein level, we used a SILAC-based quan-
titative proteomics approach to measure protein abundances in control, hLRRK2, and
hLRRK2 (R1441C) overexpressing flies.
First, we performed an in-depth quantitative proteomics with biological duplicate on
control, hLRRK2 and LRRK2-R1441C transgenic PD-like flies. Figure 3.9 shows the
schematic representation of experimental steps for typical quantitative proteomics that
are obtained from LC-MS/MS analysis of Lys-C digest mixtures. For the analysis,
approximately 100 Drosophila heads were collected from each time point and protein
isolation were performed with a buffer containing 4 % SDS to extract all proteins from
the tissue sample. To monitor time dependent changes flies at day 1, 10 and 30 were
collected. For the measurements, equal amounts of the SILAC spike-in (a pool of 1,10,30
days labeled flies) were mixed 1:1 at each time point according to their protein concen-
trations.
After in solution digestion with LysC, peptides were separated by 4h reversed phase
gradients and analyzed with a quadrupole Orbitrap mass spectrometer, see 3.9. We
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Figure 3.9: Experimental workflow for quantitative proteomics and phosphopro-
teomics analysis. SILAC mixtures, a pool of 1, 10, 30 days old Lys-6 labeled heavy fly’s
head, were spiked into 1,10, 30 days old control hLRRK2 (Wt) and hLRRK2 (R1441C)
flies. The samples were then subjected to in-solution digestion and two independent
experiments were performed using a nano UHPLC-QExactive mass spectrometer setup.
The schematic spectra depicts typical SILAC pairs. For the enrichment of phosphopep-
tides, we used 30 days old flies and performed SCX fractionation and titanium dioxide
beads (TiO2 ).
measured three different time points day 1, day 10, and day 30 each in biological du-
plicates (n=2). Mass spectrometric data were further analyzed using the MaxQuant
software package (Version 1.4.0.2) and overall we identified 2970 proteins. We found
more than 2100 identified proteins overlap in three time points for both transgenic and
control flies as shown in fig. 3.10 A.
To determine the global protein changes between control and transgenic flies, we applied
principle component analysis (PCA). Our data showed a clear segregation between day
1 and later time points (day 10 and day 30) in the first two components. In addition,
we observed a profound separation between the hLRRK2 and hLRRK2 (R1441C) at
day10/30 (blue and green ellipse), indicating the different cellular function for the sub-
stituted hLRRK2 (R1441C) compared to overexpression of the regular hLRRK2 form
(fig. 3.10 B).
Among the identified proteins, we were able to robustly quantify 1821 proteins (65 % of
all proteins) over all three time points between biological duplicates of control, hLRRK2,
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Figure 3.10: A) Venny diagram represents the number of identified protein overlap
in Wt and Mut hLRRK2 at different disease stages. Both Wt and Mut preserves the
maximum number of proteins at all stages. C) Principle component analysis of Wt and
Mut LRRK2 at different time points. At day 1, it shows similar proteomic expression
between Wt and Mut LRRK2. However, expressions are different from each other at
day 10 and day 30.
and hLRRK2 (R1441C) transgenic flies (fig.3.11 A).
Next we considered how many proteins were significantly regulated in mutant transgenic
flies compare with hLRRK2 transgenic flies at each time point. Table 3.11 B showed the
summaries of quantified proteins numbers for mutant flies compared with hLRRK2 flies
from duplicate analyses. Overall, 87 proteins were significantly (p value <0.5 % and fold
changes > 1.5) regulated in 1 day old mutant flies, however, these numbers considerably
increased with the disease progression in transgenic lines (152 regulated genes in 10 days
and 181 in 30 days). Therefore, this data may suggest a progressive perturbation due to
hLRRK2 (R1441C) toxicity in Drosophia brains. To validate the reproducibility of the
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Figure 3.11: A) Bar diagram represents the number of quantified proteins in hLRRK2,
mutant and control flies at 1, 10 and 30 days. Approximately 1800 proteins were
quantified in all measurements. B) The table indicates the number of significantly
regulated candidates based on p values and fold changes (p value <0.5 % and fold
changes > 1.5) in hLRRK2 (R1441C) flies compared with hLRRK2 flies.
experiments, correlation clustering, based on Pearson’s correlation, has been measured
over protein expression levels of all 2970 expressed proteins across indicated Drosophila
samples. We observed that Pearson’s correlations for most of the biological duplicates
were above 0.8, however the highest correlation (> 0.91) was found between the pro-
teins expression of 30 days old mutant flies. Hence, this correlation matrix among our
Drosophila samples reflects the quantitative robustness of the measurement (fig.3.12).
In order to obtain protein changes over time, a k-means clustering were performed and
protein profiles with similar regulations were grouped into different clusters (fig.3.13
A). Among 8 generated clusters, cluster 1 contains 25 proteins which were up-regulated
over the entire time period and these genes could be directly associated with hLRRK2
(R1441C) toxicity since they are independent of disease or ageing. Interestingly, protein
Pugilist (Pug) from cluster 1 had an enhanced expression at all time points in hLRRK2
(R1441C) flies. Pug is reported to be associated with interconvension of tetrahydrofolate
pathways [157]. In addition, pug was also regulated in a study by Feany and co-workers
which showed that pug has an increased abundance in tau and αS transgenic flies [158].
Furthermore, cluster 4 and cluster 8 also showed potentially interesting candidates with
a positive or negative trend and late onset (after day 10). For example, the microtubule
cytoskeleton associated protein Strn-mlck was found to be upregulated in mutant flies
after 10 days [159]. Conversely, the protein purple showed a clear down regulation after
10 days.
To characterize differences of gene ontology terms between both hLRRK2 strains, we
calculated enrichment values and plotted them against the respective p-values for anno-
tation categories (GO-term and KEGG) by employing a fisher exact test implemented
in the software tool Perseus (fig. 3.13 B). Fisher’s exact test estimates the probability of
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Figure 3.12: Pearson correlation clustering from all single-shot MS measurements.
The replicate from all 30 days flies showed correlation over 0.85 from all measurements.
getting the observed data, and all data sets with more extreme deviations. Our enrich-
ment analysis showed that both hLRRK2 and hLRRK2 (R1441C) flies are different from
their wild type alleles in terms of neurological system process, synapse and phototrans-
duction. For example, synapse linked annotations like GO biological process ’synaptic
vesicle’ and ’synapse part’ were highly (2 times) enriched in hLRRK2 (R1441C) flies
compared to hLRRK2 and control flies.
3.4.1 Transgenic hLRRK2 (R1441C) flies showed age-depending pro-
tein changes in brain tissue compared to the overexpression of
hLRRK2
Since Parkinson’s-associated neuronal degeneration is highly age dependent, we wished
to follow protein abundances over time in our transgenic fly models. To identify po-
tential targets for LRRK2 and its substituted version, we compared flies expressing
hLRRK2 and LRRK2 (R1441C) over a time period of 30 days. We calculated the class
of proteins based on p-values (p < 0.05) and protein ratios (fold change > 1.5) , which
were significantly regulated between the control and both LRRK2 transgenic strains,
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Figure 3.13: A) The cluster analysis of all time points illustrated the number of genes
that were regulated over the PD progression. B) The enriched annotation by Fisher‘s
exact test with FDR cutoff= 2 % and S0 fold-change cutoff = 4.
respectivly. The direct comparison of hLRRK2 and hLRRK2 (R1441C) flies revealed
an age-dependent increase of regulated proteins indicated by red and green circles (fig.
3.14). In total, 1422 proteins were quantified at day 30 and 181 regulated proteins (∼
12%) were detected to be regulated. Among the regulated candidates, we found 98 of
them to be down regulated and 83 of them upregulated in hLRRK2 (R1441C) compared
to hLRRK2 transgenic flies.
In addition, 77 candidates out of 181 differentially expressed proteins (∼ 42%) were
quantified with a minimum of six peptides from each independent measurement. Next
we selected some regulated genes based on statistical analysis and listed them in the
table 3.15.
In total, 83 proteins showed a clear up regulation in hLRRK2 (R1441C) flies compared
to control and hLRRK2 flies during aging, suggesting an accumulation of proteins due to
increased hLRRK2 (R1441C) levels (Table. 3.11 B). For example, we observed several
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Figure 3.14: Reproducible quantification in protein groups within replicates. A,B)
Logarithmic protein ratios (hLRRK2(R1441C)/hLRRK2 flies) were plotted for 1 day,
10 days, and 30 days old flies with two biological replicate. Up and down-regulated
proteins are indicated by red and green respectively.
proteins that are associated with the actin cytoskeleton, mitochondria, and oxidative
stress. The identification of three actins (Act88F, Act79B, and Act87E) with increased
levels supports the association of LRRK2 to cytoskeletal actin filaments [160] and previ-
ously it was shown that LRRK2 has a physiological role in cytoskeletal dynamics [161].
Interestingly, Act88F and Act79B have a high sequence similarity with mouse Actb and
Actg1 which were known as interacting partners of endogenous LRRK2 in mouse [161].
These actin cytoskeletal proteins disturbances are also in line with previous studies of
Drosophila PD models [162, 163] and thus, it indicates that the actin cytoskeletal pro-
teins are tightly associated with LRRK2 activity and may have a role in the onset of
PD symptoms in flies.
Oxidative stress is a risk factor to develop PD and it has been shown that gluthatione-
S-transferases S1 (GstS1) function as a cellular defense against toxic agents and radicals
[164]. GstS1 was already documented for its predominant expression in flight muscles,
however, it was also identified in other tissues including the nervous system [165]. This
protein catalyzes the conjugation of reduced glutathione to the products of reactive
oxygen species [166] and oxidative stress is a major contribution factor for sporadic PD
[167]. Previous study on GstS1 function suggested that increased GstS1 rescues DA
degeneration in a Drosophila model of PD [164]. Here, we also observed a clear up
regulation of GstS1 in 30 days old hLRRK2 (R1441C) flies compared to hLRRK2 flies.
Thus, increased expression of GSTs is most likely an adaptive mechanism to protect
cells from oxidative stress in response to neurodegeneration.
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Figure 3.15: List of significant candidates in mutant hLRRK2 flies compare with Wt
flies at 30 days. Up-regulated candidates are mostly from cytoskeleton and mitochon-
drion whereas down-regulated proteins are from neuronal cell bodies and membranes.
Mitochondrial dysfunction is known as one of the biochemical hallmark of sporadic PD
[168] and we found several upregulated mitochondrial proteins, including three members
of the complex V (ATP synthase subunit d, b, f) and the ATP synthase-coupling factor
6. Proteome studies of human substantia nigra showed high abundant ATP synthase
D chain in PD patients compared with age matched controls [169] and promisingly our
result also showed upregulated ATP synthase subunit d in mutant flies. The consistency
of upregulated ATPsyn-d in the human substantia nigra of PD patients and hLRRK2
(R1441C) Drosophila PD model further indicates similar mechanisms of the PD between
human and flies. Therefore, the increased levels of these mitochondrial gene expression
suggesting a dysregulation of the mitochondrial respiratory chain in hLRRK2 (R1441C)
overexpressing flies. However, the association of the LRKK2 function and mitochondrial
activity is still unclear.
Chapter 3. Results 57
Figure 3.16: Retinal degeneration due to ddc-Gal4 driven hLRRK2 (R1441C) overex-
pression in DA neurons of Drosophila. 4 weeks old mutant flies show mild but visible
retinal degeneration (black arrows) compare with others.
Another interesting candidate with a clear association to PD is the Drosophila Arg-
onaute (Ago2) protein, a splicing regulator, in hLRRK2 (R1441C) expressing flies [170–
172] . It has been reported that Ago2 is required to silence transposable elements in
somatic tissue and moreover Ago2 mutations is leading to a reduced lifespan and pro-
gressive memory impairment [173–175].
Previously it was reported that membrane associated proteins were perturbed in PD
model Drosophila [162, 163] and in line with that findings, we observed several differ-
entially expressed membrane associated proteins such as Protein retinal degeneration B
(rdgB), Serine/threonine-protein phosphatase (rdgC), Eye-specific diacylglycerol kinase
(rdgA), Innexin (inx2) and Chaoptin (Chp). Drosphila rdgC is highly abundant not
only in the compound eye but also in the photoreceptor-containing organ, optic lobes,
ocelli and in the mushroom bodies of central brain [176]. However, it is also assumed to
be involved in rhodopsin regeneration. The molecular function of rdgC gene is to inhibit
light-induced retinal degeneration in Drosophila and rdgC mutants lead degeneration of
photoreceptors cells [177]. Since we quantified few downregulated retina associated genes
in mutant flies, next we examined the eyes of 30 days old hLRRK2, hLRRK2 (R1441C)
and control flies. Interestingly we observed mild but obvious structural abnormalities in
30 days old mutant flies retina compared with control flies, see fig. 3.16.
Besides these regulated actin cytoskeleton, mitochondria and membrane associated pro-
teins, we also detected several proteins connected to neuronal functions and plasticity
with significant down regulation over the entire data set. Interestingly, cluster 8 revealed
a class of proteins mainly involved in synaptic plasticity that were only down regulated
in hLRRK2 (R1441C) flies compared to control flies as shown in fig. 3.13 A. Synaptic
vesicles (SV) recycling process is an important step for the release of neurotransmit-
ter and activation of postsynaptic receptor channels. Mainly three proteins, such as
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Synaptobrevin, Syntaxin 1A, and SNAP-25 form the core of the SNARE complex (sol-
uble attachment NSF protein receptor) mediates the vesicle formation and fusion [178].
Dysregulation of syntaxin and synaptobrevin in flies leads to defects in neurotransmis-
sion [179, 180] and deficiency in SNAP-25 (synapto-some-associated protein 25kDa) was
associated with neuronal disorders in humans [181]. Here, we found two SNARE core
proteins SNAP-25 and Syntaxin are down regulated in hLRRK2 (R1441C) compared
to hLRRK2 flies. Similarly, the exocytosis related proteins synaptotagmin (Syt1) and
the Ras-related protein (Rab-3) showed also exclusively decreased levels in hLRRK2
(R1441C) flies compared to control and hLRRK2 flies. Synaptotagamin (Syt1) is a
presynaptic Ca2+ sensor for neuroendocrine cell function and an essential part for Ca2+
triggered exocytosis in neurons. It is also known as a molecular marker for adaptive
changes in excessive neuronal activity during epileptic seizures comes from [182]. Of
note, a loss of syt1 was discovered in human hippocampus of patients with Alzheimer’s
disease [183] and promisingly, our proteome data also showed the down regulation of
syt1 in mutant flies compared with hLRRK2 flies. On the other hand, Rab3 is linked
both in exo and endocytic trafficking of SV vesicles and thus, we reasoned that hLRKK2
(R1441C) dependent downregulation of several SV proteins could lead to a dysregulation
vesicle formation and recycling leading most likely to an imbalance of synaptic plasticity
in DA neurons.
It has been shown that hLRRK2 (R1441C) caused reduced dopamine and other cate-
cholamines synthesis in cultured adrenal chromaffin cells isolated from hLRRK2 (R1441C)
KI mice [184]. Strikingly, we detected three down regulated proteins, including punch
(GTP cyclohydrolase), purple (6-pyruvoyl tetrahydrobiopterin synthase) and henna which
are all involved in dopamine synthesis in Drosophila. Protein henna is a phenylalanine
hydroxylase which catalyzes phenylalanine conversion to tyrosine and tyrosine is a ma-
jor substrate for dopamine and other catecholamine synthesis. In humans, a mutation
in GTP cyclohydrolase (GTPCH) and 6-pyruvoyl tetrahydrobiopterin synthase (PTS)
causes childhood parkinsonism-dystonia characterized by decreased levels of dopamine
and serotonin [185]. Moreover, a 50% reduction of tetrahydrobiopterin levels which is
synthesized by the enzymes GTPCH levels, were also observed in sporadic PD patients
[186]. Of note, punch seems to be more down regulated in the presence of αS compared to
αS (A53T) overexpression [158]. Therefore, our results demonstrate a clear link between
hLRRK2 (R1441C) and several enzymes involved in catecholamine biosynthesis.
3.4.2 Validation of selected candidates from proteome data
Western blot analysis was performed in order to validate protein expression changes
observed in our mass spectrometric data. For example, Drosophila Protein argonaute-2
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Figure 3.17: Validation of proteomics data. A) MS spectra of peptide sequences for
Tan (Upper) and AGO2 (Lower). C) Western blots showed the upregulation of AGO2
protein and down regulation of Tan protein in mutant flies compare with hLRRK2 flies.
(encoded by AGO2) was selected and the mass spectra for Peptide sequence SQDAEGW-
TAQK belonging to AGO2 showed up-regulation in hLRRK2 (R1441C) flies compared
with heavy internal standard, whereas spectra remains unchanged in hLRRK2 flies based
on the relative intensities of the peaks (3.17 A). In line with our proteomics data, West-
ern blot analysis also showed up-regulation of the AGO2 in mutant flies compare with
hLRRK2 flies, see fig. 3.17 B. For the second blot analysis, a differentially expressed
candidate, protein Tan, was selected which showed down-regulation in the proteomics
data. The blot analysis also detected down regulated band at 43 kDa as shown in fig.
3.17 B, in mutant flies as previously described [187]. Protein Panactin was used as a
loading control since its expression did not change in mutant flies in comparison with
hLRRK2 controls flies.
In addition, we performed immunocytochemistry to follow the cellular localization of the
Tan protein. The hydrolsye Tan had shown 2-fold decrease in our MS data. Therefore, we
have chosen this protein to validate our proteomics data by using an immunohistological
approach. Tan has been shown previously to impact dopamine levels by hydrolysing N-
beta-alanyl dopamine (NBAD) to beta-alanine and dopamine, respectively [188]. Flies
lacking Tan have disturbed dark pigmentation due to reduced dopamine and melanin
levels in the skin and Tan function is crucial for light detection by converting carcinine
to histamine [188].
Tan expressing neurons were visualized on head-cryosections of adult flies using an
affinity-purified anti-Tan antibody [187]. As an internal control, we have applied an
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Figure 3.18: Immunocytochemical labeling of tan and nc82 in Drosophila head.
When comparing 30 days old control, hLRRK2 with hLRRK2 (R1441C) flies, an overall
decrease of tan protein (violet) is observed in mutant. Nc82 protein (green) is used as
control which is unchanged in all genotypes.
anti-Bruchpilot (NC82) antibody, generated in a different species than anti-Tan. Bruch-
pilot is a pan-neuronal expressed synaptic protein [189]. Hence, we did not expect
changes in its expression level due to heterologous expression of hLRRK2 or hLRRK2
(R1441C) in only DA neurons. Four-week-old ddc-Gal4 flies were used as control geno-
type. Both, Tan and Bruchpilot expression levels were quantified on confocal images.
As compared to the control hLRRK2, flies expressing hLRRK2 (R1441C) showed about
25 % reduction of Tan expression and about 55 % reduction compare with ddc-gal4 flies
as shown in fig. 3.18. As expected the anti-Bruchpilot labeling did not vary in between
the three genotypes. The experiment was repeated 4 times yielding similar results.
3.4.3 Protein interaction of differiantilly expressed proteins of trans-
genic hLRRK2 (R1441C) flies map illustrates strong intermolec-
ular connection
We next integrated the Search Tool for Retrieval of Interacting Genes (STRING) analysis
ofDrosophila protein interaction network in order to check the hypothesis that regulated
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Figure 3.19: String subnetworks interaction maps of selected regulated proteins from
different cellular compartment in mutant flies. Green and red arrows represent the
upregulated and downregulated candidates respectively and these small lists show most
of the connected candidates within this network were already regulated in mutant flies.
proteins may be connected by intermolecular interactions.
Therefore, we searched for regulated proteins from different compartments such as mi-
tochondria, membrane etc. against a comprehensive Drosophila interaction network
database. Fig. 3.19 shows a detailed network maps for rdgA, synaptotagmin and ATP-
syn d proteins. We found that these three proteins have strong interaction subnetworks
where most of the proteins within the networks were already found as regulated in our
proteome data. For example, network analysis of membrane associated protein, rdgA,
showed the high interconnection with other membrane linked proteins such as rdgC,
norpA, rdgB, which were already found to be down regulated in hLRRK2 (R1441C)
flies. Further, the neuronal protein synaptotagmin (Syt) is tightly associated with other
neuronal proteins, including Snap25 and Syx1A, which were also down regulated in the
hLRRK2 fly model. Taken together, the unbiased protein quantification approach con-
firmed several known PD related proteins and we found common molecular pathways
which are equally affected in fly the human PD patients.
3.5 Proteome expression of αS Drosophila model of PD
In order to emphasize on hLRRK2 (R1441C) specific toxicity in PD flies, we next in-
vestigated the protein expression changes in the αS PD model and two fly strains with
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Figure 3.20: Principle component analysis of ddc-Gal4 driven control, αS, A30P-αS
and A53T-αS flies show the global proteome difference at day 1 and day 10.
a point mutation in the Synuclein at position A53T and A30P [71]. All experiments
were performed based on SILAC approach and biological duplicates on ddc-Gal4, αS,
A30P-αS and A53T-αS transgenic PD-like flies between day 1, 10 and day 30. The
experimental setup was kept similar as discussed previously. Quantitative proteomics
were performed with two biological duplicate on ddc-Gal4, αS, A30P-αS and A53T-αS
transgenic PD-like flies. In total, 4432 proteins were identified and 1980 proteins were
quantified between control, two αS mutants and αS transgenic flies. Similar the hRLLK2
model a PCA analysis showed clear separations between control and mutant flies. We
found four well separated clusters in PCA and ddc-Gal4 flies did not show significant
proteome differences between 1, 10 and 30 days. Nevertheless, significant changes were
observed in αS and mutants flies, specially A30P-αS flies showed a noticeable proteome
changes compared with αS and A53T-αS flies in both in 1 day and 10 days as shown in
fig. 3.20.
3.6 Transgenic hLRRK2 and αS flies show common and
distinct age-dependent protein changes
To identify common and distinct protein changes of both PD models, hierarchical clus-
tering was performed with the normalized expression profiles of transgenic hLRRK2,
hLRRK2(R1441C), αS, A30P-αS, and A53T-αS overexpressing flies. In our study, the
hierarchical clustering determined the biological relationship between individual genes
in all transgenic and control flies. Notably, the analysis revealed a clear time-dependent
separation between all hLRRK2 and αS strains, see fig. 3.21.
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In addition, the analysis revealed several clusters with commonly regulated proteins. For
example, General odorant-binding protein 99a (Obp99a) in cluster 1 was upregulated
in both hLRRK2 and S transgenic flies. The Obp99a protein is expressed in olfactory
sensory dendrites and it is thought to be associated with capturing and transporting
hydrophobic odorants in flies [190]. On the other hand, cluster 2 represents the down-
regulated proteins mostly associated with larval serum protein (LSP) in both hLRRK2
and αS transgenic flies compare with heavy flies although they showed unchanged ex-
pression between the transgenic flies. Next, we detected several proteins connected to
neuronal functions and plasticity with significant down regulation over the entire dataset.
Of particular interest is cluster 3 which revealed a class of proteins mainly involved in
synaptic plasticity that were only down regulated in hLRRK2 (R1441C) flies compared
to all αS transgenic and control flies.
To make hLRRK2 (R1441C) associated genes constitute a specific hLRRK2 (R1441C)
signature, we compared the proteome changes of 30 days old hLRRK2(R1441C) flies
and A53T-αS with respect to control flies and plotted against each other as shown in
fig. 3.22.
A direct comparison of protein changes in hLRRK2 (R1441C) to A53T-αS showed a
rather weak Pearson correlation of 0.3 (fig. 3.22). However, a group of actin cytoskeleton
associated regulated proteins, including TpnC4, Act88f, up, GstS1 and Strn-Mlck were
up regulated in both mutant strains at day 30. Similar, the elevated expression of glu-
tathionine family member GstS1 in A53T-αS and hLRRK2 (R1441C) flies might reflects
the defensive response against A53T-αS and hLRRK2 (R1441C) toxicity as discussed
previously. Similarly, we also observed increased puglist protein levels in hLRRK2 and
αS transgenic flies [158]. Interestingly, the downregulated candidates revealed a class
of proteins mainly involved in synaptic plasticity which were only down regulated in
hLRRK2 (R1441C) flies compared to αS transgenic and control flies as shown in fig.
3.22. For example, Synaptotagmin, Syntaxin 1A, SNAP-25, Rab3 and shi were down-
regulated only in hLRRK2 (R1441C) flies which are linked with the vesicle formation
and fusion, table. 3.23.
3.7 Quantitative proteomics of A30P-αS Drosophila model
of PD at presymptomatic stage
Next we examined the proteome expression changes in αS and A30P-αS flies. We de-
tected 163 proteins which were significantly regulated (p < 0.05) in A30P-αS flies rel-
ative to αS flies. Among these regulated candidates, 93 candidates were upregulated
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Figure 3.21: Hierarchical clustering of quantified proteins between hLRRK2, αS and
control flies. Both αS and hLRRK2 transgenic flies demonstrated their distinct cluster
compared with each other.
and 70 were downregulated. Table 3.1 denotes significant proteins that were differen-
tially expressed in 10 days old A30P-αS flies compared with αS flies. A total of twelve
upregulated proteins were associated with actin cytoskeleton related proteins including
GstS1 and calpain. Calpain is a calcium dependent intracellular protease which acts
as a leading candidate for the degradation of receptors and many cytoskeletal proteins
were known to be degraded by calpain. Drosophila calpain has been reported as a or-
ganizer of cytoskeletal structure related to actin and similar to the hLRRK2 (R1441C)
fly model actin cytoskeletal associated proteins such as, Troponin T and Act88f were
also up regulated in the A30P-αS fly model [191, 192]. Connversely, several heat shock
proteins, including Hsp27, Hsp26 and Hsc70-1. Hsp27 were quantified with increased
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Figure 3.22: Scatter plotting with quantified proteins from A53T-αS and hLRRK2
(R1441C) flies compared with control flies.
Figure 3.23: List of significant candidates in hLRRK2 (R1441C) flies compare with
LRRK2 flies and A53T-αS flies.
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abundance in A30P-αS flies. Member of the small heat shock family have different
functional relevance in autophagy, aging and neurodegeneration [193, 194].
For example, Hsp27 null mutant flies showed short life, however overexpression of Hsp27
increases the lifespan and prevents mosaic eyes from cellular toxicity [195–197]. Since,
heat shock proteins act as a defense system in response to various stress conditions,
elevated expression of Hsp proteins might be an adaption during the progression of the
αS induced PD in flies.
Table 3.1: Significantly regulated proteins between 10 days old A3oP and αS flies
Gene names Flybase Protein IDs A3oP/αS A3oP/αS Peptides P-value
Log2 Ratio E1 Log2 Ratio E2
CtsB1 FBgn0030521 Q9VY87 2.13 2.03 5 0.02406
Vps13 FBgn0033194 A1Z713 2.10 2.11 55 0.00205
Obp99b FBgn0039685 Q9VAI6 1.20 1.18 9 0.00125
Gbs-76A FBgn0036862 Q9VVY3 1.11 1.08 6 0.00146
wupA FBgn0004028 P36188 1.01 0.74 33 0.05350
Fbp1 FBgn0000639 Q04691 1.01 0.96 3 0.00259
AIF FBgn0031392 Q9VQ79 1.00 1.15 11 0.02341
Hsp26 FBgn0001225 P02517 0.91 1.03 4 0.01301
TppII FBgn0020370 Q9V6K1 0.91 0.77 41 0.01431
CalpA FBgn0012051 Q11002 0.89 0.98 13 0.00707
Map205 FBgn0002645 P23226 0.89 0.68 25 0.03049
Hsp27 FBgn0001226 P02518 0.88 0.99 6 0.01126
Acp36DE FBgn0011559 Q9V3R1 0.82 1.09 10 0.05799
GstS1 FBgn0010226 P41043 0.78 0.74 12 0.00184
Aats-gln FBgn0027090 Q9Y105 0.78 0.85 19 0.00447
Act88F FBgn0000047 P83967 0.78 0.67 20 0.00802
fln FBgn0005633 P35554 0.77 0.75 13 0.00025
TotA FBgn0028396 Q8IN44 0.75 0.90 4 0.01657
betaCop FBgn0008635 P45437 0.73 0.59 14 0.01385
Strn-Mlck FBgn0265045 A1ZA66 0.72 0.85 122 0.01259
Cyp313a1 FBgn0038236 Q9VFJ0 0.71 0.85 17 0.01339
TpnC73F FBgn0010424 P47949 0.71 0.75 10 0.00152
Gpo-1 FBgn0022160 Q7K569 0.69 0.68 34 0.00008
Hsc70-1 FBgn0001216 P29843 0.68 0.59 13 0.00547
Tm1 FBgn0003721 P49455 0.68 0.95 24 0.04967
CG12400 FBgn0031505 Q9VQM2 0.66 0.65 5 0.00012
mt:ND3 FBgn0013681 P18930 0.66 0.66 2 0.00001
ND42 FBgn0019957 P91929 0.66 0.68 13 0.00021
sec3 FBgn0086475 Q9VVG4 0.61 0.59 12 0.00026
Pu FBgn0003162 P48596-2 0.59 0.65 11 0.00184
ND75 FBgn0017566 Q94511 0.59 0.61 21 0.00011
pr FBgn0003141 P48611 0.58 0.60 5 0.00049
Dms FBgn0011581 P61849 -0.62 -0.85 2 0.02991
Esyt2 FBgn0039208 Q9VC62 -0.62 -0.43 20 0.02035
CG15117-RB FBgn0034417 Q7K173 -0.62 -0.49 10 0.01211
smp-30 FBgn0038257 Q9VFG5 -0.63 -0.67 13 0.00316
Cyp12e1 FBgn0037817 Q9VGZ0 -0.63 -0.62 8 0.00064
CG3590-RA FBgn0038467 Q9VEP6 -0.67 -0.41 13 0.03258
Cpr57A FBgn0034517 Q7K5J8 -0.68 -0.85 4 0.02097
CG17549 FBgn0032774 Q0E8P1 -0.69 -1.09 2 0.05928
CG10688 FBgn0036300 Q9VTZ6 -0.71 -0.49 7 0.02705
Sac1 FBgn0035195 Q9W0I6 -0.72 -0.35 9 0.05392
Pbprp3 FBgn0011281 P54193 -0.73 -0.81 4 0.00762
ATPCL FBgn0020236 E2QCF1 -0.73 -0.70 32 0.00169
GstE4 FBgn0063496 A1ZB69 -0.88 -0.57 7 0.04351
UGP FBgn0035978 E1JI91 -0.89 -0.69 25 0.02481
Cyp6g1 FBgn0025454 Q9V674 -1.04 -0.67 10 0.05413
PIP5K59B FBgn0034789 Q9W1Y3 -1.15 -1.35 7 0.02607
Cyp6a20 FBgn0033980 Q9V773 -2.48 -2.70 15 0.02411
Among the downregulated cluster, several transmembrane and neuron associated pro-
teins were found to be down regulated in A30P-αS flies compared with αS flies. For
instance, the transmembrane protein Dystroglycan (Dg) is linked with a distrophin com-
plex, which relates extracellular matrix to cytoskeletal actin and it was documented
as a possible reason for muscular dystrophy and brain defects in human [198–200].
Drosophila Dg mutants show a similar phenotype with a progressive muscular dys-
trophy and neuronal degeneration. The finding that Dg is reduced in A30P-αS flies may
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reflect brain abnormalities and leading finally to the PD phenotype. Another interest-
ing down regulated protein is the phosphatidylinositide phosphatase Sac1, which highly
expressed in the Drosophila nervous system [201]. This protein is known to play an
important role in various kinds of cellular process, including synaptic morphology and
intercellular trafficking [202]. Drosophila Sac1 mutant showed defect in dorsal closure
and axonal pathfinding which caused neurodegeneration in dosage dependent manner
[203]. Thus, The inactivation of Sac1 in Drosophila showed a defect in dorsal closure
and axonal path finding leading to neurodegeneration.
Taken together, although both A30P-αS and hLRRK2 (R1441C) flies models showed
similar cytoskeletal actin remodeling phenotypes, reflecting a common and more general
event during the progression of the PD in Drosophila, proteome expression in A30P-αS
Drosophila model of human neurodegentive disease speculates that the overwhelming
majority of mitochondrial proteins associated with A30P-αS were highly distinct.
3.8 Quantitative proteomics of A53T-αS Drosophila model
of PD at presymptomatic stage
Next, we performed the quantitative proteome analysis of 10 days A53T-αS flies in
comparison with αS flies. In total, we quantified 60 proteins which were differentially
expressend in A53T-αS flies and have been shown in table 3.2. Although 45 % signifi-
cant proteins are ovelapped with A30P-αS flies, a fraction of 27 proteins were exclusively
regulated in A53T-αS flies.
Among the actin cytoskeleton related proteins, two upregulated Gst family members,
namely GstE1 and GstE7 were identified in A53T-αS and it is worth noting that, in-
creased GstE1, GstE7 expression was also found in hypoxia induced neurodegenerative
Drosophila model [204].
Therefore, the high expression level of Gst family members in mutant flies might reflect
that cells may encountering stress condition which may trigger Gst expression to protect
DA neurons. However, it is completely unclear why only A53T-αS overexpressing flies
showing this specific up regulation of two Gst family members.
In addition, six mitochondrial associated proteins, including Probable cytochrome P450
12c (Cyp12c1), Cytochrome P450 9b2 (Cyp9b2), Probable cytochrome P450 6a20 (Cyp6a20),
CG5703, Gpo-1 and Sdhb were also up regulated in A53T-αS flies. Cytrochrome p450
isoenzymes were found in human PD patients [205] and Cytrochrome p450 is associated
to molecular detoxification. Hence, regulated three Cytrochrome p450 family members
might represent their functional significance in the pathogenesis of PD in mutant flies.
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Table 3.2: Significantly regulated proteins between 10 days old A53T and αS flies
Gene names Flybase Protein IDs A53T/αS A53T/αS Peptides P-value
Log2 Ratio E1 Log2 Ratio E2
GstE1 FBgn0034335 Q7KK90 1.52 1.74 8 0.04972
CG1665-RA FBgn0033451 A1Z803 1.35 1.25 6 0.00738
Cyp12c1 FBgn0036806 Q9VVR9 1.02 1.06 6 0.00965
lectin-28C FBgn0040099 Q9VLW1 1.00 0.58 6 0.03407
Aats-ile FBgn0027086 Q8MSW0 0.96 1.07 32 0.04936
RanGap FBgn0003346 Q9VIW3 0.96 0.95 8 0.02140
prtp FBgn0030329 Q9VYV3 0.86 0.86 20 0.00005
Obp99b FBgn0039685 Q9VAI6 0.83 0.82 9 0.00141
msk FBgn0026252 Q9VSD6 0.83 0.59 11 0.01843
GstE7 FBgn0063493 A1ZB72 0.78 0.82 6 0.01560
Strn-Mlck FBgn0265045 A1ZA66 0.73 0.62 122 0.03925
mRpL12 FBgn0011787 Q9VSR5 0.70 0.37 9 0.04578
up FBgn0004169 P19351 0.69 0.72 56 0.01363
Pu FBgn0003162 P48596 0.67 0.71 11 0.01648
Tm1 FBgn0003721 P49455 0.65 0.81 24 0.01415
TotC FBgn0044812 Q8IN43 0.63 0.63 2 0.00109
fln FBgn0005633 P35554 0.62 0.66 13 0.01638
TotA FBgn0028396 Q8IN44 0.61 0.95 4 0.05211
Jabba FBgn0259682 Q7K1Q6 0.58 0.65 5 0.03852
GstS1 FBgn0010226 P41043 0.58 0.57 12 0.00130
tobi FBgn0261575 Q9VBR6 -0.60 -0.64 11 0.03845
Yp1 FBgn0004045 P02843 -0.61 -0.41 13 0.03506
Cpr49Ab FBgn0050042 A1Z8Y3 -0.64 -0.66 3 0.00864
CG17121 FBgn0039043 Q9VCR9 -0.66 -0.57 6 0.03540
CG12926 FBgn0033437 A1Z7X8 -0.68 -0.34 10 0.05396
GstE4 FBgn0063496 A1ZB69 -0.69 -0.67 7 0.01547
Cpr30F FBgn0051876 Q8IPD8 -0.73 -0.44 4 0.03327
CG9675 FBgn0030773 Q9VXC9 -0.93 -1.16 5 0.00615
Cpr57A FBgn0034517 Q7K5J8 -1.03 -1.02 4 0.00151
CG5706 FBgn0039175 Q9VCA5 -1.10 -1.21 12 0.02937
Obp83b FBgn0010403 Q23970 -1.24 -1.82 6 0.01939
CG8329 FBgn0036022 Q9VT23 -1.37 -1.15 3 0.00555
Cyp6a20 FBgn0033980 Q9V773 -3.18 -3.23 15 0.00138
On the other hand , Glycerophosphate oxidase-1(Gpo-1), a mitochondrial inner mem-
brane protein, regenerates the NAD+ for glycolysis continuation and Drosophila Gpo
mutant is flightless [206]. Promisingly, our previous study of hLRRK2 (R1441C) flies
also showed high expression of Gpo-1. Thus, elevated expresson of Gpo-1 in PD model
transgenic flies might indicates its role in mitochondrial system that may lead to high
oxidative stress in mutant flies.
Besides regulated mitochondrial proteins, synaptic vesicle linked protein Rab18 was also
regulated in A53T-S expressing flies. In Drosophila, cellular expression of the Rab18
protein is neuron specific and colocalizes with Rab5. The significance of Rab18 function
in the Drosophila synaptic system, trafficking have been already reported and Drosophila
mutated Rab gene showed a wide range of neurological disease phenotypes [207–210].
We quantified a regulated Rab gene namely, Rab18 in mutant flies that exhibits neu-
ron specific or neuron enriched expression and colocalizes with Rab5. Previously we
found the synaptic vesicle trafficking linked proteins were significantly regulated due to
hLRRK2 (R1441C) overexpression in flies and thus, regulated Rab18 in mutant A53T-
αS flies may also reflect may also reflect the functional association of synaptic vesicle
proteins in PD.
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Figure 3.24: A) Class 1 and Class 2 Phosphorylation-sites analysis. B) The distri-
bution of the pY/pS/pT phosphoproteome. C) Hierarchical clustering of quantified
phosphoproteins. Some clusters are expressed at higher (red) or lower (blue) levels in
mutant flies compared to control flies. Higher magnification of some cluster is shown
in the heatmap. Red and blue colors indicating normalized and z-score ratios (n=3).
3.9 Phosphoproteome analysis of hLRRK2 (R1441C) trans-
genic flies
Reversible protein phosphorylation is an important regulatory element for cell signaling
and rapid adaption to internal and external stimuli. Moreover, a global view on the
protein phosphorylation status in living animal models will help to learn more about
activated pathways. Thus, a comprehensive analysis of phosphorylation patterns in flies
overexpressing different PD related proteins will give more insights into the pathobiology
of the disease. The analysis of transgenic flies overexpressing hLRRK2 and its mutant
forms might allow us to get a deeper understanding of the LRRK2 kinase function and
activated signaling pathways during the disease progression.
3.9.1 Global phosphoproteome analysis of hLRRK2 (R1441C) mutant
flies in PD
In order to identify potential hLRRK2 targets, we set out to analyze the phosphopro-
teome in control, hLRRK2, and hLRRK2 (R1441C) overexpressing 30 days old flies.
Similar to the proteome analysis, we used the SILAC fly approach as an internal pro-
tein standard for accuarate phosphopeptide quantification and performed a biological
triplicate for each fly strain (n=3). The experimental design for the phosphorylation
analysis for hLRRK2 and hLRRK2 (R1441C) expressing 30 days old flies was shown
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in fig. 3.9. Briefly, extracted proteins from head tissue (∼ 1mg) were digested in so-
lution. The phosphopeptides enrichment was done by separating the peptide mixtures
with SCX chromatography followed by using titanium dioxide (TiO2) extractions [211].
Each fraction was analyzed by 2.5h liquid chromatography gradients and measured with
a quadrupole orbitrap mass spectrometer followed by analyzing the raw datas by Max-
Quant software (1.5.0.0).
In total, 5518 phosphopeptides were identified and 2529 were quantified in at least two
independent experiments. A fraction of 4202 phosphorylation sites (class I ) were de-
tected with localization probability > 0.75. In the case of multiple serines, thereonines,
or tyrosines are present in the amino acid sequence, the probability to detect specific
phosphorylation site localization is at least 75 % within different potential phospho-
rylated site locations (fig. 3.24 A). Localized phosphorylation sites with a probability
> 75 % are termed class I sites and were considered for the further analysis. . The
majority of detected class I phosphopeptides had one (61.47 %), two (23.18 %) and
three (15.34 %) phosphorylated sites. Moreover, the detected phosphorylation sites are
comprised of 88 % serine, 11 % threonine and 1 % tyrosine sites as shown in fig. 3.24 B.
One likely reason for less identified tyrosine phosphorylated sites could be that tyrosine
phosphorylation may occur on less abundant proteins compared to serine and threonine
phosphorylation. Secondly, tyrosine is less stable in phosphoamino acid analysis than
serine and threonine, which makes it more challenging to be identified.
Next, we clustered the SILAC ratios of enriched phosphopeptides from control, hLRRK2
and LRRK2 (R1441C) flies and observed for several GO-terms, including mitochondrial
biogenesis and synaptic vesicle formation, clear differences. For example, microtubule
related candidate, futsch is highly phosphorylated in hLRRK2 (R1441C) flies compared
with control and hLRRK2 expressing flies, see 3.24 C.
The fig. 3.25 showed high reproducibility of our quantitative phosphoproteome data.
The Pearson correlations for ddc-Gal4, hLRRK2 and hLRRK2 (R1441C) were between
0.88 , 0.81 and 0.87 respectively.Therefore, the experimental setup can be used to analyze
accurately phosphopeptide and its changes between different conditions.
The comparison of control and hLRKK2 overexpressing flies revealed 23 regulated phos-
phosites (fig. 3.26 A) and 39 regulated sites for hLRRK2 (R1441C) flies . The direct
comparison between both hLRRK2 and hLRRK2 (R1441C) mutant showed for 51 phos-
phopeptides an upregulation and 32 were quantified with a reduced phosphorylation.
However, normalization according to the protein level and statistical calculation using
a permutation based false discovery (FDR) rate < 5 % revealed for only 8 phosphosites
a significant regulation as shown in fig. 3.26 B. As some of the significant regulated
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Figure 3.25: Reproducibility for phophoproteomics experiment between control,
hLRRK2 and hLRRK2 (R1441C) flies.
phosphorylated sites were not quantified in the protein level, they were taken off, con-
tributed for less quantified number after normalization. For example, Chro and Ptp61f
were not considered as regulated candidates, since their corresponding SILAC protein
ratio were not detectable. Table 3.26 C showed a list of significant candidates, including
their amino acid sequence window, positions within the protein, log2 ratio, and p-value .
Selected SILAC pairs of unmodified peptides and phosphopeptides from Synaptojanin,
futsch and Ankyrin 2 are shown in fig. 3.27. Offnote, Futsch is already known to be
phosphorylated by hLRRK2 [212] and therefore, it underscores our accurate quantita-
tive phosphoproteomics approach. The Drosophila protein Futsch, is the orthologue of
the mammalian microtubule associated protein (MAP1B), which plays a central role
in synaptic morphogenesis. Our phosphoproteome data showed that futsch is highly
phosphorylated (9.54 and 1.77 fold-change) at S4106 and S4909 by hLRRK2 (R1441C)
compared to the hLRRK2 overexpressing condition, see 3.26 C.
In addition, we also detected enhanced phosphorylation levels of several proteins which
are tightly associated to synaptic vesicle formation. For an example, Synaptojanin
(Synj), a polyphosphoinositide phosphatase [213], is a presynaptic protein, localized
presynaptically at the motor neuron synapse terminal and promotes synaptic vesicle
(SV) uncoating [214]. Synj inactivation leads to endocytosis impairment and disrupted
vesicle recycling process in Drosophila. Remarkably, the human SYNJ1 mutation was
reported as a cause of early onset parkinsonism and defective recycling of the synaptic
vesicle in the pathogenesis [215]. Notably, the sequence alignment of the fly, mouse/rat,
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Figure 3.26: A) Volcano plot of phosphopeptide ratios between hLRRK2 and control
flies with normalization. The y-axis and x-axis represents the -10log (adjusted p-value)
and t-test difference (log2 ratio between hLRRK2 and control flies) respectively. B)
Phosphopeptide ratios between mutant and hLRRK2 flies were plotted without and
with normalization. Significant phosphoproteins changes are labeled with blue (up)
and red (down) circle. C) List of significantly regulated phosphoproteins with their
sequence and phosphorylated positions.
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Figure 3.27: MS Spectra for Phosphorylated Synaptojanin, futsch and ank2.
and human synaptojanin protein sequence revealed a conservation of the T1131 site, see
fig. 3.28 and recent global phosphorylation studies also showed that Synaptojanin is
phosphorylated at a threonine (T1220) in humans [216] as well as in rats (pT1217)[217].
Taken together, the global phosphopeptide analysis revealed a hLRRK2 (R1441C) de-
pendent regulation for 8 sites and the synaptic vesicle protein Synaptojanin showed an
enhanced phosphorylation at position T1331.
3.9.2 In− vitro kinase assay revealed increased human Synj1 phospho-
rylation by hLRRK2 (R1441C) compared to hLRRK2
In order to validate the Synaptojanin phosphorylation mediated by hLRRK2 an in −
vitro kinase assay were performed. The conservation of the T1131 site on synapto-
janin and its phosphorylation in flies, mouse/rat, and humans point to a more general
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Figure 3.28: The sequence similarirties of regulated phosphorylated sites of significant
candidates between human, fly and mouse.
mechanism to regulate the activity of Synaptojanin by LRRK2 under regular and dis-
eased conditions. Here we performed an in − vitro kinase assays, using three different
hLRRK2 recombinant proteins, including hLRRK2, hLRRK2 (R1441C), and hLRRK2
(D1994A) in combination with the recombinant human Synj1 as a potential target for
the LRRK2 kinase. Recombinant LRRK2 proteins were incubated with the recombi-
nant human Synj1 for 1h at 300C to allow phosphorylation by the LRRK2 kinase in the
presence of radioactive labeled ATP (γ- 32P). After 1 hour of incubation, the reaction
was terminated by adding 4x SDS sample buffer followed by denaturation at 1000C for
10 minutes. The samples were run on SDS-PAGE gel for 3 hour and the dry gel was
subjected to autoradiograhy. Since the hLRRK2 (D1994A) protein has no kinase activ-
ity, we used this recombinant protein as a negative control for our kinase assay [218] and
the assay revealed no phosphorylation of synaptojanin under this conditions. In con-
trast, the combination of hLRRK2 and Synaptojanin revealed a clear phosphorylation
in a dose dependent manner and the incubation with the LRRK2 inhibitor LRRK2-IN-1
inhibited the phosphorylation of Synaptojanin about 60 % (fig. 3.29 A).
In correlation to our quantitative phosphoproteomics experiments, the hLRRK2 (R1441C)
mutant form showed the strongest phosphorylation of Synaptojanin and we also observed
an elevated autophosphorylation of the hLRRK2 (R1441C) recombinant protein. Simi-
larly, the incubation with the hLRRK2 kinase inhibitor reduced the Synaptojanin and
hLRRK2 (R1441C) phosphorylation at similar doses as shown in fig. 3.29 B. These
results indicate that both recombinant proteins are able to phosphorylate Synaptojanin
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Figure 3.29: LRRK2 phosphorylates synaptojanin. A) Kinase assay with GST-
LRRK2 was incubated with increasing amounts of LRRK2-IN-1. Kinase assay with
recombinant hLRRK2 protein was subjected to Western blotting for detection of GST-
tagged LRRK2 and Synaptojanin. B) As in (a) except GST-LRRK2 (R1441C) was
utilized. C) LRRK2, R1441C and D1994A recombinant proteins were incubated sepa-
rately with Synj for 0 and 60 minutes. Mixtures were subjected to MS analysis to find
the phosphorylated sites and phosphorylation activity of Synj at T1259 was found to
be regulated by LRRK2 (R1441C). Intensities were log2 transformed and signficiance
was assesed by an unpaired t.test assuming equal variances.
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and that the mutations within the GTPase domain results in enhanced kinase activity
and Synaptojanin phosphorylation. Complementary, we used the same experimental
conditions with non-radioactive ATP to measure the phosphorylation of Synaptojanin
and hLRRK2 forms with our mass spectrometric workflow. As shown in fig. 3.29 C, we
detected the pT1259 site to be phosphorylated and the incubation with the hLRRK2
(R1441C) clearly increased the Synaptojanin phosphorylation at T1259. Conversely,
the hLRRK2 (D1994A) had no influence on the phosphorylation of Synaptojanin.Of
note, we detected 6 phosphorylation sites on hLRRK2 and 4 of them (pT1343, pT1348,
pT1452, pT1503) are localized within ROC domain confirming the autophosphoryla-
tion of LRRK2 [219]. Although both LRRK2 and LRRK2 (R1441C) showed similar
autophosphorylation signal, synaptojanin did not show any autophosphorylation signal
and the hLRRK2 (D1994A) kinase dead mutant together with Synaptojanin also did not
show any phosphorylation signals ( fig. 3.30 A-B). In addition, Synaptojanin phospho-
rylation was effectively competed with non-radioactive ATP in the presence of LRRK2
and LRRK2 (R1441C) (fig. 3.30 C-D). The MS/MS spectra for phosphorylated peptide
of synaptojanin has been shown in fig 3.30 E. These results indicate that both recombi-
nant proteins are able to phosphorylate Synaptojanin and that the mutations within the
GTPase domain results in enhanced kinase activity and Synaptojanin phosphorylation.
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Figure 3.30: LRRK2 phosphorylates synaptojanin. A) Autophosphorylation of
LRRK2, LRRK2 (R1441C) and synaptojanin. Recombinant proteins were subjected to
Western blotting for detection of GST-tagged LRRK2 and R1441C in the presence of
γ- 32P-ATP. B) Kinase dead LRRK2 (D1994A) mutant did not phosphorylates Synap-
tojanin. C) Phosphorylation of synaptojanin by hLRRK2 (R1441C) with different
concentrations of LRRK2 ATP. D) As in (C) except LRRK2 was utilized. E) MS/MS
spectra for phosphorylated peptide of synaptojanin.
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3.10 Immunoprecipitaion of hLRRK2 in Drosophila brain
revealed several synaptic proteins as potential inter-
action partners
To identify direct hLRRK2 interactors in our PD model, a protein-protein interaction
screen based on Flag-Tag immunoprecipitation were used. For immunoprecipitation ex-
periments, we used a mouse-monoclonal Flag antibody in order to enrich for potential
binding partners of hLRRK2 in fly brains.
To distinguish between interactors and background binders, the extracts from ddc-Gal4
flies were used. MS analysis and label free protein quantification revealed 25 putative
interactors with p-values < 0.05 and fold-change > 2 (n=2) as shown in table 3.31.
However, 500 proteins were discarded as nonspecific binders since they were equally
abundant in all genotypes. Among 25 interacting partners, 11 genes were associated
with synaptic vesicle recycling process, 4 were membrane linked genes. A complete list
of hLRRK2 interacting genes were shown in fig. 3.31. Strikingly, we quantified 8 known
LRRK2 binding partners, including Endophilin, Rab7, futsch, Synapsin, the vesicle fus-
ing protein (Nsf2) from our analysis [212, 214, 220, 221]. Those interactors reflecting
the crucial function of LRRK2 during synaptic vesicle formation and highlighting the
sensitivity of our immunoprecipitation experiments. Notably, we also found futsch as up
regulated phosphorylation site in our phosphoproteomic study, suggesting that hLRRK2
(R1441C) might directly interacts and phosphorylates these proteins. Another known
hLRRK2 interator is dynamin, a microtubule associated protein regulating the vesicu-
lar trafficking processes [222]. Here, we identified the Drosophila orthologe Shi with a
fold-change > 2.06 (p-value < 0.005). Similarly, we found a 3.6 fold-change for ankyrin
2 a cytoskeleton protein responsible for the stabilization of microtubule associated neu-
romuscular junctions (NMJ). Of note, we observed an increased phosphorylation close
to the c-terminus at position S11169 in LRRK2 (R1441C) overexpressing flies.
These potential interacting partners suggested the functional connection of LRRK2 with
mitochondrial proteins, membrane proteins and synaptic vesicle associated proteins.
The identification of LRRK2 interaction partners may therefore ensure the better un-
derstanding of the physiological function of LRRK2 and associated PD pathology.
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Figure 3.31: Interactome proteomics for hLRRK2 in Drosophila. A) Volcano plot of
protein ratios between hLRRK2 and control flies. The y-axis and x-axis represents the
log (adjusted p-value) and t-test difference (log2 ratio between hLRRK2 and control
flies). All the known hLRRK2 interacting partners were colored by green (circle) and
the provable interactors were colored by blue circles.
Table 3.3: Potential interacting partner of hLRRK2 in Drosophila
Protein Ids GENE NAME IP ratio LRRK2/Control P value
Q5S008 lrrk2 14.11938039 0.0011
P15348 top2 8.997250174 0.0152
Q94920 porin 3.992056948 0.0196
Q9VLZ7 Cyp4d21 5.407541241 0.0014
Q9VG82 Cyp9f2 3.104322186 0.0018
Q9VE00 Cyp12a4 3.6359091 0.0043
Q8T0M9 Got2 3.84074511 0.0211
Q95U34 Galk 2.465127805 0.0138
P06002 ninaE 5.031092037 0.0001
P13677 inaC 2.709395708 0.0137
Q24008 inaD 3.130948481 0.0014
Q09103 rdgA 2.431195319 0.0008
P48159 RpL23 2.211324598 0.0000
Q9W596 futsch 2.892511878 0.0030
Q0E8H3 ank2 3.601410971 0.0354
P92177 14-3-3ep. 3.177910342 0.0017
Q7KU82 smid 3.750714699 0.0093
P54351 Nsf2 3.098467001 0.0107
Q24546 syn 2.981817378 0.0012
P15372 Arr1 2.980567968 0.0003
P46461 comt 2.792264823 0.0005
B5RIU6 endophilin 4.116709105 0.0035
O76742 rab7 2.039112968 0.0084
P25228 rab3 2.026335716 0.0015
E1JJA4 shi 2.055630435 0.0055
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Discussion
The molecular mechanisms leading to neuronal degeneration in PD or Amyotrophic
lateral sclerosis (ALS) are poorly understood and disease modifying treatment is un-
til now also not available. To gain a better understanding of the pathophysiology of
these neurodegenerative diseases, several model organisms, including yeast, flies and ro-
dents were established that overexpress a human gene and its disease associated gene
variants. In this study, the fruit fly D.melanogaster has been used as a PD model
system to understand the pathobiology of the PD associated gene hLRRK2. Further-
more, we generated another PD fly model by overexpressing αS to find common and
gene specific mechanisms during the progression of PD. Though flies appear far away
from human physiology, similar cellular process, including gene activities, and signaling
pathways are conserved in the fly model, which are comparable to the human system
[223]. Furthermore, the fly is one of the most striking model organisms for Parkinsonism
research due to its complex DA system regulating motor activities such as climbing and
flying. The DA system in Drosophila consists of mainly 5 distinct clusters within the
protocerebrum of the fly brain. Each cluster contains several hundreds of dopamine
producing neurons and similar to the human system, each cluster projects their axons
into different functional areas of the brain. So far, the anatomy of DA neurons and
their projections were mainly studied using reporter strains such as TH-specific GAL4
line and immunohistochemical approaches using anti-TH antibodies [71]. In addition,
the short life span further emphasizes the fly model as a versatile tool to investigate the
progression of the PD in a relative short time period. Thus, PD fly models recapitulate
some features of the human disease and can be used to model human neurodegenerative
diseases. In the present study, a hLRRK2 (R1441C) Drosophila strain was generated
as a new PD model by overexpressing the human LRRK2 gene containing an amino
acid exchange at position 1441 (R1441C) in Drosophila(DA) neurons under the control
of ddc-Gal4 line. The study above showed that overexpression of the hLRRK2 and its
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mutant form hLRRK2 (R1441C) in flies initiated severe degeneration of retinal and DA
neurons, shorter life span and locomotor impairment compared to age matched control
flies. Moreover, flies overexpressing the hLRRK2 (R1441C) mutant exhibited a more
severe phenotype compared to hLRRK2 overexpressing flies. Since locomotor activity is
tightly associated with viable DA neurons [224, 225], we used an immunohistochemistry
approach to visualize TH positive neurons in fly brains and found significantly reduced
levels of TH positive neurons in several DA clusters, including PPM1/2 PAL, PPL1,
PPL2 a/b. Consistently, hLRRK2 (R1441C) flies showed a more severe phenotype com-
pared to control flies, suggesting enhanced toxicity of the R1441C LRRK2 version which
is also associated with enhanced kinase activity [57]. Although there is substantial ev-
idence that LRRK2 (R1441C) does not increase in vitro kinase activity [219], however,
when using the LRRK2 pS1292 antibody as a marker of autophosphorylation activity,
R1441C does increase kinase activity [56]. Moreover, it is also possible that DA neurons
are still present but do not express TH. Further marker proteins, including dopamine
transporter (DAT) should be tested to trace DA neurons and their connections to other
brain areas during disease progression [226]. The present results correlate with previous
works from Liu and Karterina [72, 74] showing also the degeneration of DA neurons in
hLRRK2 transgenic fly brains. Interestingly, the PPM1/2 and PPL1 cluster showed the
most severe reduction of TH positive neurons in aged hLRRK2 (R1441C) flies compared
to hLRRK2 and ddc-Gal4 control flies. DA neurons project long axons to distinct func-
tional areas of the brain. It might be possible that DA neurons with longer projections
are more affected by the overexpression of hLRRK2 and its mutant form. Conversely,
some clusters such as the PPM3 and PAM cluster showed no significant change in TH
positive neurons between control, hLRRK2 and hLRRK2 (R1441C) transgenic flies.
However, this data is contradictory with a previous finding [72] where all DA clusters
were equally affected. This might reflect different expression levels of the Gal4 activator
protein between different fly strains and laboratory conditions. In addition, these differ-
ences might be due to the utilization of different methods monitoring DA neurons. For
example, TH reporter strains such as TH-mCD8::GFP expression does not completely
overlap with anti-TH antibody staining. Other reasons could be an unequal tissue prepa-
ration, causing differences in the detection of brain proteins, the transgene copy number
or expression levels or differences between LRRK2 mutations. The apparent differences
of DA clusters in the present work might be due to different sensitives between subclasses
of DA neurons to the toxic effect of hLRRK2 overexpression. Notably, the ectopic over-
expression of hLRRK2 (R1441C) under the control of the elav-Gal4 driver results in a
milder phenotype compared to ddc-Gal4 driver system. It is tempting to speculate that
the weaker elav-dependent expression due to lower Gal4 levels from the elav promoter
might result in lower levels of hLRRK2 and thereby causing a milder PD phenotype.
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Previous work from Sang and Wang [224, 225] reported that inhibition of Hsp90 chaper-
one function radically declines LRRK2 stability in primary neuronal cultures, suggesting
Hsp90 as a useful target for suppressing the accumulation and pathogenic activity of PD
related LRRK2 mutations in neurons. They also showed a clear correlation between lo-
comotor impairment and DA neuron degeneration. Interestingly, Ng et. al [73] did not
observe any significant locomotor dysregulation in hLRRK2 (G2385R) overexpression in
flies. The mutations at amino acid position 2385 is in the WD40 domain and the miss-
ing phenotype may reflect reduced kinase activity for this LRRK2 mutation [227]. A
report from Katerina et. al [74] using different LRRK2 Drosophila strains (WT, Y1699C
and I2020T) presented the ectopic expression of WT or mutant LRRK2 in DA neurons
caused severe neuronal loss accompanied by complex age-dependent changes in loco-
motor activity. Surprisingly, they showed an improved climbing ability after an initial
locomotor impairment period and progressive DA degeneration in transgenic flies. They
suggested that compensatory mechanisms between DA and non-DA neurons might res-
cue the phenotype. However, other reports excluded such a scenario and observed a
clear proportional relation between reduced DA neurons and climbing disability [78].
Besides a reduced locomotor activity flies overexpressing hLRRK2 showed a reduced
life span, and a significant retinal neurodegeneration in hLRRK2 and hLRRK2 trans-
genic flies compared to Canton S and GMR-Gal4 flies. These results are consistent
with the results of Liu et. al and Katerina et. al [74], however Ng et. al did not observe
any retinal degeneration in any LRRK2 expressing Drosophila lines (WT, Y1699C and
G2019S). Ng et. al showed that the coexpression of human parkin in LRRK2 (G2019S)
expressing flies protects against the DA degeneration that occurs with age. On the other
hand, Elliot CJ et. al revealed that overexpressing LRRK2-G2019S in flies DA neurons
leads to progressive loss of photoreceptor function. They also found elevated autophagy,
apoptosis and mitochondrial disorganization in photoreceptor cells. The head sections
demonstrated an extensive neurodegeneration throughout the visual system, including
regions not directly innervated by DA neurons in these flies [228].
These variations between the present hLRRK2 (R1441C) transgenic flies and the previ-
ous work are probably due to different fly strains in combination with various expression
constructs optimized for protein expression. It is also important to note that the same
pathogenic LRRK2 mutation can also vary between different LRRK2 patients [229].
Taken together, the morphometric analysis and TH expression profile supports an im-
portant function of hLRRK2 and its mutant form hLRRK2 (R1441C) in DA neurons of
flies. Although anatomical data concerning neuronal clusters are slightly incongruent in
the literature, in many cases, LRRK2 overexpression results in a clear PD phenotype.
However, the mechanistic details how the multi-enzymatic LRRK2 and its mutation
variant influences DA neurons remains unclear.
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4.1 Quantitative proteome analysis of hLRRK2 (R1441C)
overexpressing flies revealed specific changes related
to PD
In order to get more insight into the biochemical alterations induced by hLRRK2 and
its mutant variant, a comprehensive quantitative MS analysis was performed. The un-
biased screen of diseased flies revealed several hundreds of regulated proteins during
early and late time points and the detection of several known PD related proteins and
their related pathways are an excellent validation of our model system. Most interest-
ingly, several regulated proteins were detected which have no obvious connection to the
pathobiology of PD. Two independent biological replicates have been performed for day
1, day 10 and day 30 and proteins with 1.5 fold change (p < 0.05) were considered as
significantly regulated candidates. A class of regulated proteins in hLRRK2 (R1441C)
flies were only regulated during early time points (day 1 and day 10) and showed an
equal distribution at later stages. We hypothesized that mutant flies might have en-
countered an unfavorable environment which was further compensated for later stages.
Since, PD is an age dependent progressive neurological disorder, the analysis was there-
fore focused more on proteins which demonstrated late onset regulation. In total, 183
proteins have been quantified with an exclusive regulation at day 30. A Fisher’s exact
test showed for those late regulated proteins, an enrichment of Gene Ontology (GO)
terms specific for microtubule based processes and synaptic vesicles. In addition, the
KEGG pathway analysis also demonstrated the enrichment of pathways related to “ox-
idative phosphorylation”, “Parkinson’s and Alzheimer’s disease”. The term oxidative
phosphorylation indicates mitochondrial energy production, mitochondrial function and
has been reported to be tightly linked to different neurological disorder, including PD
[230]. Another class of proteins known to be involved in cytoskeletal rearrangements
during PD is microtubule and actin filament related proteins. Actin cytoskeletal pro-
teins are widely known not only for their functional role in dynamic cellular processes,
but also for their important function during neuronal development. Further, neuronal
migration and neurite extension relies on actin-regulatory proteins such as moesin, ezrin,
and radixin also known as ERM proteins. In addition, actin polymerization [231] and
myosin heavy chain (MyHc) proteins are also important factors for the regulation of the
actin based cytoskeleton [232]. A recent study showed that hLRRK2 (G2019S) overex-
pression in primary neurons from rat brains results in an inhibition of neurite outgrowth
suggesting a direct function as a modulator for actin dynamics during neurite extension
[161]. Conversely, LRRK2 knockout or silencing leads to increased neurite outgrowth
suggesting that LRRK2 is a negative regulator of neurite outgrowth/complexity [233].
However, it is unclear whether LRRK2 functions as a scaffold protein or regulates actin
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dynamics via its kinase and/or GTPase domain. A first indication for a direct link
between the actin cytoskeleton and the LRRK2 kinase activity was shown by the phos-
phorylation of moesin at pT558 mediated by the hLRRK2 (G2019S) mutant variant in
vitro kinase assays. However, this has never been confirmed in cells or tissues. What
is more, moesin required heating to allow its phosphorylation by LRRK2 suggesting
it only occurs when unfolded/denatured [234]. The phosphorylation of ERM proteins
results in the activation of these proteins and induces the localization of F-actin to the
plasma membrane and regulating thereby the formation of filopodia and neurite out-
growth. The overexpression of the hLRRK2 (G2019S) mutant also results in increased
levels of F-actin and this upregulation inhibits the interplay between actin filaments and
microtubule structures. Thus, elevated F-actin levels induced by hLRRK2 (G2019S)
may act as an obstruction and thereby preventing neurite outgrowth. The quantitative
proteome analysis revealed no changes for ERM proteins but a significant increase for
two actin orthologs Act87E and Act88F in hLRRK2 (R1441C) flies at day 30. Feany
et al previously raised the possibilities of actin cytoskeletal changes as important medi-
ators of toxicity in Drosophila taupathies and reported the direct interaction between
actin and tau [235]. Taken together, our study of hLRRK2 (R1441C) and hLRRK2 flies
showed again that the regulation of the actin cytoskeleton is tightly associated with a
correct LRRK2 function and abundance. However, the direct functional relationship of
hLRRK2 with these two actin cytoskeleton proteins (Act87E and Act88F) needs to be
addressed in future experiments.
4.2 LRRK2 overexpression affects several cellular compart-
ments
Previous studies have shown that the expression of mutated hLRRK2 (G2019S) in DA
neurons causes a functional and anatomical loss of a Drosophila’s visual system [72].
Here, we observed a mild but clear malformation in the eyes of hLRRK2 (R1441C)
overexpressing flies along with several down regulated proteins associated with the pho-
toreceptor cell membrane. There are three types of DA neurons innervating the visual
system, the PPL neurons in the lobula, MC neurons in the medulla, and LA neurons
which project from protocerebrum to lamina. PPL neurons only project to the lobula,
well away from photoreceptor terminals and there is also no known direct synaptic con-
nection between MC dendrites and photoreceptor axons [228]. Thus, LA DA neurons
might be mostly responsible for neurotransmission to photoreceptor terminals. We ob-
served that expression of hLRRK2 (R1441C) in DA neurons results in an anterograde
degeneration of photoreceptors and most likely explains the eye phenotype.
Chapter 4. Discussion 85
4.2.1 Mitochondrial disruption in LRRK2 (R1441C) expressing flies
Mitochondrial dysfunction is a known biochemical hallmark of PD [168] and most likely
one of the most important reasons for the sporadic appearance of PD in humans. LRRK2
plays a vital role in modulating mitochondrial activity and primary fibroblasts from PD
patients carrying a LRRK2 mutation showing impaired mitochondrial function and mor-
phology [236]. Recent studies reported a direct association of LRRK2 expression and
mitochondria dynamics. For example, correct mitochondrial function is connected to
fusion and fission processes of mitochondria and increased mitochondrial fragmentation
was further exacerbated by LRRK2 (R1441C) [237]. Wang et al reported that LRRK2-
induced mitochondrial fragmentation could be due to enhanced fission, reduced fusion or
both. By using photo-convertible fluorescent labeling, they demonstrated that a reduced
fusion is involved in the process. In total, 63 mitochondrial proteins (5 % of all proteins)
were identified reflecting the abundance of mitochondria in neuronal tissue. The GO
and KEGG pathway analysis revealed a fraction of 12 regulated mitochondrial proteins
were also involved. The final step for energy production is the generation of ATP by
several ATP synthase proteins within complex V of the respiratory chain. In total, 5
ATP synthases were up regulated in hLRRK2 (R1441C) expressing flies. One feature
of DA neurons is the highly efficient transport of ions through the plasma membrane
after each action potential. This is a highly energy demanding process and takes over
40% of the total energy requirement for cells of the nervous system [238]. One possible
explanation for an increased level of ATP synthases could be that mutant flies might
require more ATP synthase enzymes to provide enough energy to compensate for more
inefficient ion transport and signaling in the presence of LRRK2 (R1441C).
4.2.2 Synaptic vesicle proteins are regulated by LRRK2 (R1441C)
The physiological relevance between increased levels of LRRK2 and synaptic vesicle traf-
ficking has been shown by several reports [160, 239, 239]. In line with these observations,
we also discovered several significantly down regulated proteins in LRRK2 (R1441C)
flies which were associated with endocytosis and exocytosis. The question remains how
LRRK2 (R1441C) overexpression disturbs the synaptic vesicle trafficking system, in-
cluding endocytosis, exocytosis, and neurotransmitter release. The transportation of
vesicles from the reserve pool relies on mitochondrial ATP. After docking and prim-
ing, the SNARE complex and accessory proteins (e.g., Synaptotagmin and CDCRel-1)
facilitate SV fusion with the plasma membrane allowing for neurotransmitter release.
Endophilin, Dynamin, and Rab5 participate in the retrieval and transport of SVs by
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endocytosis. Although the clear scenario of LRRK2 (R1441C) molecular mechanism in
association with synaptic vesicles still needs to be examined, our proteomics data out-
lined the possible function of LRRK2 mutant in endocytosis and exocytosis disruption
in Drosophila. The quantitative proteomics data showed that synaptic transmission
linked proteins such as Syntaxin and SNAP-25, proteins of the t-SNAREs complex, are
significantly downregulated in hLRRK2 (R1441C) flies. In addition, another synaptic
vesicle specific protein, Syanptotagmin (Syt), was also found to be downregulated in mu-
tant flies. Syanptotagmin is a key player for neurotransmitter release and is known to
interact with the carboxyl terminus of SNAP-25 and syntaxin. Hence, regulated Synap-
totagmin can disrupt LRRK2’s interaction with Syntaxin and SNAP-25 [240, 241] that
might lead to perturbed exocytosis in mutant flies. However, other reports argued that
binding between Synaptotagmin and Syntaxin may not be playing an important role for
neurotransmitter release [242]. The observation of several proteins involved in synaptic
vesicle formation confirmed that hLRRK2 is an important factor for these processes.
It is important to mention that the overexpression of WT LRRK2 in primary mouse
hippocampal neurons are associated with a decrease in SV endocytosis and results in
a lower rate of SV trafficking [243]. More recently downregulated LRRK2 function in
mouse cortical neurons was shown to affect SV recycling and redistribution supporting
the assumption that LRRK2 controls the storage and mobilization of vesicle pools in-
side the presynaptic bouton [244]. Therefore, the significant down regulation effect of
these proteins on the synaptic vesicle cycle might lead to an inefficient sequestration of
dopamine into vesicles resulting in increased cytosolic DA levels and ensuing dopamine
toxicity.
4.3 The proteome changes in αS PD model flies
In order to identify more specific hLRRK2 dependent mechanisms, further Drosophila
PD models were generated overexpressing three different variants of αS (WT, A30P,
A53T) under the control of the ddc promoter. Similar to hLRRK2 analysis, all ex-
periments were performed in biological duplicates. In contrast, for the analysis of αS
fly’s strains only day 1 and day 10 were used for the analysis, since αS flies showing a
severe PD phenotype after two weeks and most of the transgenic flies die around day
40. In total, 4400 proteins were identified from biological duplicates and 1707 candi-
dates were quantified among all αS fly strains (Wt, A30P and A53T). The strongest
effect in regard to protein changes was observed in A30P-αS flies compared to αS and
A53T-αS flies. Though the proteome response of both A30P-αS and A53T-αS mutants
showed a clear overlap of the regulated proteins (70%), each mutant strain conserves
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a specific subset of regulated proteins. For example, A30P-αS expressing flies demon-
strated increased protein levels of mitochondrial membrane respiratory chain proteins
such as NADH dehydrogenase (Complex I). Interestingly, disturbed complex I forma-
tion was documented in human PD patient’s brain tissue and it has been suggested
that disturbed mitochondrial DNA might be one of this reasons for these biochemical
dysfunction [24]. Several complex I inhibitors have been described to replicate some of
the key motor features of PD and lead to death of DA neurons. For example, parkinson-
ism in humans has been reported to result from unintentional exposure to 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) [245]. Moreover, administration of rotenone
to D.melanogaster results in levodopa-responsive locomotor deficits and loss of DA neu-
rons [246]. Therefore, differentially expressed complex I associated proteins in hLRRK2
(R1441C) flies might reflect the disturbance in the mitochondria inner membrane, which
may play a role in PD. On the other hand, A53T-αS expressing flies showed a new set
of mitochondrial proteins which were significantly regulated relative to αS flies. For
example, 3 Cytrochrome p450 proteins (Cyp9b2, Cyp12c1 and GstE1) were found to
be regulated in A53T mutant flies. Interestingly, hLRRK2 (R1441C) expressing flies
also exhibited the elevated expression of Cyp9b2 protein compared with hLRRK2 flies.
Drosophila’s Cytochrome p450 genes were also involved in neuronal defense against
oxidative imbalance under hypoxia treatment [204] and therefore, elevated expression
of Cytochrome p450 genes might represent the neuroprotective role against neuronal
degeneration in A53T mutant flies. Therefore, these data sets demonstrate the involve-
ment of various mitochondrial genes in PD progression relating to the variation of αS
mutant form in flies.
Although both LRRK2 and αS PD models showed a common set of regulated proteins
and similar phenotypes, the integrative analysis showed that LRRK2 and αS mutant
fly strains mediate their PD-induction and toxicity through different pathways. For
example, we observed several proteins involved in synaptic vesicle exo-and endocytosis
to be affected only in hLRRK2 (R1441C) flies, whereas αS overexpressing flies revealed
no changes in those vesicle proteins, suggesting a specific hLRRK2 function for this
pathway. Conversely, the down regulation of a few proteins such as Cyp6a20 showed a
specific function for αS during the progression of PD. Thus, the pathological mechanisms
in both models during the course of PD is clearly different and our analysis provides a
quantitative dataset to investigate the consequences of increased levels of LRRK2 and
αS disease associated protein changes in neuronal tissues of living flies.
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4.4 Phosphoproteome dynamics and hLRRK2 interaction
partners in a PD model
To gain a deeper insight into affected signaling pathways and to learn more about poten-
tial kinase substrates of LRRK2, a global phosphoproteome analysis of flies expressing
hLRRK2 and the mutant (R1441C) variant were performed after 30 days. In total,
2529 phosphorylation sites were identified by the in vivo SILAC approach. The com-
parison of control and hLRRK2 overexpressing flies revealed a time-dependent increase
of protein phosphorylation in the presence of hLRRK2. We quantified 27 and 39 phos-
phosites which were at least 1.5 fold regulated in hLRKK2 and hLRRK2 (R1441C) flies
respectively compared to control flies. A permutation based false discovery (FDR) rate
of < 0.05 was applied for statistical calculation and after the normalization to protein
levels, 9 significant regulated phosphorylation sites were quantified between hLRRK2
and hLRRK2 (R1441C) overexpressing flies [247, 248]. Until now, the number of iden-
tified LRRK2 kinase substrates in vitro studies is very low and none has been con-
vincingly proved in vivo, leaving the pathophysiological relevance of kinase activity
unclear. For example, Xiong et. al reported ArfGAP1 as a LRRK2 kinase substrate
in vitro and showed the phosphorylation of ArfGAP1 by LRRK2 inhibits its GAP ac-
tivity and LRRK2 kinase activity is significantly reduced in the presence of ArfGAP1
[243]. However, Stafa et. al demonstrated that co-expression of ArfGAP1 and LRRK2
synergistically promotes neurite shortening in rat primary cortical neurons in a manner
dependent upon LRRK2 GTPase activity and silencing of LRRK2 expression rescues
Arfgap1-induced neurite shortening [222]. Therefore, the effectors associated in the reg-
ulation of cellular LRRK2 phosphorylation are still unknown. A consensus phosphoryla-
tion motif based on a peptide library screen in vitro exists only for the LRRK2 (G2019S)
mutant variant [249]. Strikingly, two microtubule (MT) associated proteins futsch (in
vertebrates: microtubule-associated proteins, MAPs) and Ankyrin2 were quantified with
increased phosphorylation levels in hLRRK2 (R1441C) mutants compared to hLRRK2
flies. The MT cytoskeleton plays an important role for synaptic vesicle transportation
and maintenance of synaptic transmission and hence disruption of MT dynamics in
neuronal synapse often leads to neurological disease [250, 251]. Consistently, we also
found these two proteins in our LRRK2 interactome study, suggesting that both MT
associated proteins are direct LRRK2 interaction partners and most likely also targets
of the LRRK2 kinase. Thus, enhanced kinase activity of the hLRRK2 (R1441C) may
cause hyperphosphorylation of microtubule associated proteins and thereby altering the
binding to cytoskeletal structures. In addition, Futsch and Ank2 are responsible for the
formation of early endosomes, correct assembly of the reserve pool, and neurotransmit-
ter release within active zones [252]. However, whether the increased phosphorylation
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of futsch impedes intact microtubule structures and changes the dynamics of synaptic
vesicles remains to be elucidated. Electric stimulation of synapses causes a rapid calcium
influx and activates synaptic vesicle exo-endocytosis near the presynaptic plasma mem-
brane. Synaptic vesicle docking is mediated by a complex consisting of synaptobrevin
(VAMP), synaptotagmin, Rab3, and two components of the presynaptic plasma mem-
brane SNAP25 and syntaxin. Our study revealed a clear down regulation on protein
level for this complex, but no change in the corresponding phosphopeptides. In fact, the
R1441C mutation within the ROC domain of LRRK2 causes not only reduced GTPase
activity but has also an toxic effect on cells [243, 248]. In this context it is possible that
increased hLRRK2 (R1441C) levels cause an impairment of synaptic vesicle proteins
by suppressing synaptic vesicle trafficking. Recent studies also showed a direct asso-
ciation of LRRK2 to endosomal-autophagic processes and increased levels of hLRRK2
(R1441C) causes an accumulation of autophagic vesicles [258]. Another example for an
endogenous LRRK2 target is endophilin A (EndoA), an important regulator of synaptic
endocytosis. LRRK2 dependent phosphorylation of endophilin regulates its association
to membranes and facilitates synaptic vesicle endocytosis at Drosophila’s neuromuscu-
lar junctions [220]. Although we did not find a regulation of endophilin at the protein
or phosphopeptide level, we found increased phosphorylation of two highly conserved
sites (pT1131, pS1142) on synaptojanin a known interaction partner of endophilin [259].
In c. elegans the interaction between endophilin and synaptojanin is mediated by the
EndoA-SH3 and proline rich domain (PRD) at the c-terminus of synaptojanin. This in-
teraction is crucial for vesicle recycling and the phosphorylation of pT1131 and pS1142
may facilitate the interaction between both proteins in the fly system.
Notably, our in vitro kinase assay with human synaptojanin confirmed a direct phos-
phorylation by the hLRRK2 and moreover, we found increased phosphorylation levels
for pT1131 and pS1142 in the presence of the hLRRK2 (R1441C) variant. Thus, it
is possible that dynamic phosphorylation of synaptojanin mediated by hLRRK2 might
be a requisite for the interaction with EndoA. Alternatively, synaptojanin is a highly
dynamic protein and a reversible phosphorylation might regulate the transient recruit-
ment to synaptic vesicles. Our findings that hLRRK2 (R1441C) mutant variant enhances
Synaptojanin phosphorylation might be an important aspect for endophilin-dependent
synaptic vesicle formation under regular and diseased conditions. Clearly, perturbed
neurotransmission caused by dysregulated synaptic vesicle formation have been impli-
cated in PD.
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4.5 The functional relevance between SV trafficking dys-
function and DA degeneration
Synaptic dysfunctions have been assumed as one of the early and major neurobiologi-
cal events in several neurological diseases [260] and accumulating evidence has pointed
out the regulation of presynaptic activity by PD related genes. For example, αS-KO
(knockout) mice have lent support for a pivotal role of αS in the regulation of presynaptic
neurotransmitter vesicle pools [214]. Intriguingly, presynaptic defects such as reduced
dopamine overflow and impaired striatal synaptic plasticity have been also identified in
PINK1- and parkin-KO mice [261]. In addition, LRRK2 (R1441C) homozygous knockin
mice and the R1441G LRRK2 BAC (bacterial artificial chromosome) transgenic mice
displayed severe neurotransmission defects, including impairments in nigrostriatal DA
innervation and degeneration of the nigrostriatal projections [69, 184]. Finally, it has
been suggested that the presence of LRRK2 as an integral part of the presynaptic protein
complex might play a key role in electrophysiological properties as well as proper vesic-
ular trafficking and spatial distribution in the presynaptic pool [244]. Our proteome,
phosphoproteome and protein-protein interaction profile have outlined the potential role
of hLRRK2 (R1441C) for several cellular pathways and compartments, including mito-
chondria and synaptic vesicle formation/trafficking. Nevertheless, how does LRRK2
regulate SV dysfunction and lead to neuronal loss in the fly PD model still need to
be addressed. Although LRRK2 conserves functional domains such as the N-terminal
leucine-rich repeat domain and the C-terminal WD40 domain for protein–protein inter-
actions, it also contains an active kinase domain. Therefore, it is tempting to speculate
that LRRK2 might affect SV trafficking at different levels according to the functions
of its proposed presynaptic targets: mobilization and priming of SV, disassembling of
SNARE complex and recycling of SV. Secondly LRRK2 may disrupt SV fusion to the
presynaptic membrane by regulating synaptotagmin, a SV integral protein which acts as
a Ca2+ sensor. Moreover, LRRK2 interacts with NSF, an AAA (ATPase associated with
various cellular activities) protein responsible for the disassembling of the SNARE com-
plex [184]. Therefore, LRRK2 may also modulate the assembly–disassembly equilibrium
of SNARE complexes by the LRRK2-NSF interaction. Finally, Rab5, a key regulator of
vesicle endocytosis, has been demonstrated as an interacting partner of LRRK2. Inter-
estingly, it has been shown that overexpressed Rab5 rescued endocytosis defects caused
by LRRK2 overexpression [263]. Our study showed that SV cycling associated proteins
and their phosphorylation are significantly regulated by LRRK2 at different steps of this
process starting from the reserved pool (RP) to the early endosome (fig. 4.1B). Thus
SV trafficking dysregulation of specific proteins and phosphorylation sites induced by
the LRRK2 kinase could interrupt dopamine homeostasis that may result in increased
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Figure 4.1: Synaptic vesicle trafficking system in Drosophila. Green arrow denotes
down regulated proteins ratios in mutant flies, whereas red arrows represent the reg-
ulated phosphorylated site compared to hLRRK2 flies. The interaction partners were
shown by circled arrow (Blue circled arrow).
pools of cytosolic DA, which is an oxidative stressor for the neuronal cells [264]. A
previous report also suggested that DA can alter αS and induce toxic protofibrils [265].
Therefore, the neuronal degeneration in PD might be the result of extra cytocolic DA
release.
Taken together, our MS study provides a comprehensive quantitative dataset of the
human LRRK2 and human αS Drosophila Parkinson’s models. In addition, our phos-
phoproteomics analysis of hLRRK2 (R1441C) overexpressing fly mutants revealed novel
LRRK2 substrates, including several synaptic vesicle proteins, with increased phosphory-
lation. The identification of specific LRRK2 (R1441C) dependent phosphorylation sites
will provide important clues to which pathways are activated in hLRRK2 (R1441C) over-
expressing flies and we hope our analysis will help to discover new targets for therapeutic
treatments PD.
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[19] Christoph B Lücking, Alexandra Dürr, Vincenzo Bonifati, Jenny Vaughan,
Giuseppe De Michele, Thomas Gasser, Biswadjiet S Harhangi, Giuseppe Meco,
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